Characterisation of molecular mechanisms involved in nevirapine- induced hypersensitivity by Cornejo Castro, Elena Maria
  
 
 
Characterisation  of  molecular  
mechanisms  involved  in  nevirapine-
induced  hypersensitivity 
  Thesis submitted in accordance with the requirements of the University of Liverpool for the degree of Doctor in Philosophy   by   
Elena Maria Cornejo Castro March 2014 
 
 
  
ii 
 
 
Declaration This thesis is the result of my own work. The material contained within this thesis has not been presented, nor is currently being presented, either wholly or in part for any other degree or qualification.  
 Elena Maria Cornejo Castro             This research was carried out in the Department of Molecular and Clinical Pharmacology, in the Institute of Translational Medicine, at the University of Liverpool.   
  iii 
 
 
Acknowledgements 
   To everyone who has contributed to this thesis:  Thank you, Danke, Zikomo, Cheers, Terima kasih, Hvala, Gracias, Tapadh leibh, 
A’inya,	  Xiè xie, Grazie, Diolch, Obrigada, Kob khun ka, Go raibh maith agaibh, Merci, Shukria, Do jeh,  
Ta’     
iv 
Contents ACKNOWLEDGEMENTS ................................................................................................................. III PUBLICATIONS AND COMMUNICATIONS ................................................................................... V ABSTRACT ........................................................................................................................................ VII ABBREVIATIONS .......................................................................................................................... VIII 
CHAPTER 1: GENERAL INTRODUCTION .................................................................................... 1 
CHAPTER 2: VALIDATION OF DIFFERENTIAL EXPRESSED GENES AND IN VITRO ANALYSIS OF NEUTROPHIL ANTIGEN CD177 ........................................................................ 54 
CHAPTER 3: CD177 GENE POLYMORPHISMS: ANALYSIS OF THE ASSOCIATION WITH NVP HYPERSENSITIVITY AND CD177 PROTEIN EXPRESSION ........................................... 85 
CHAPTER 4: EXPRESSION ANALYSIS OF MIR-148A IN NVP-TREATED TOLERANT AND HYPERSENSITIVE PATIENTS .................................................................................................... 104 
CHAPTER 5: ANALYSIS OF CIRCULATORY MIRNAS IN HYPERSENSITIVE AND TOLERANT NEVIRAPINE-TREATED PATIENTS ................................................................... 127 
CHAPTER 6: HLA-ASSOCIATIONS WITH NEVIRAPINE-INDUCED HYPERSENSITIVITY: A SYSTEMATIC REVIEW OF THE LITERATURE AND META-ANALYSIS .......................... 150 
CHAPTER 7: FINAL DISCUSSION ............................................................................................. 175 APPENDICES .................................................................................................................................. 184 BIBLIOGRAPHY ............................................................................................................................. 195     
  v 
Publications and communications 
Published papers Carr D.F., Chaponda M., Jorgensen A.L., Castro E.C., Van Oosterhout J.J., Khoo S.H., Lalloo D.G., Heyderman R.S., Alfirevic, A., Pirmohamed, M. (2013). ASSOCIATION OF HUMAN LEUKOCYTE ANTIGEN ALLELES AND NEVIRAPINE HYPERSENSITIVITY IN A MALAWIAN HIV-INFECTED POPULATION. Clin Infect Dis, 56, 1330-9.  
Manuscripts in preparation 
Cornejo Castro E.M., Carr D.F., Jorgensen A.L., Alfirevic A., Pirmohamed M. (2014). HLA-ALLELOTYPE ASSOCIATION WITH NEVIRAPINE-INDUCED HYPERSENSITIVITY: A SYSTEMIC REVIEW OF THE LITERATURE AND META-ANALYSIS.  
Cornejo Castro E.M., Carr D.F., Chaponda M., Jorgensen A.L., Rainbow L., Lane B., Ebrahimi B., Khoo S., Lalloo D.G., Alfirevic A., Cossins A.R., Pirmohamed M. (2014). TRANSCRIPTOMIC ANALYSIS INDENTIFIES DIFFERENTIAL REGULATION OF NEUTROPHIL ANTIGEN CD177 MRNA BUT NOT PROTEIN, IN NEVIRAPINE-TREATED HYPERSENSITIVE AND TOLERANT HIV-1 PATIENTS FROM MALAWI.  Carr D.F., Bourgeois S., Chaponda M., Cornejo Castro E.M., Alfirevic, A., Khoo S.H., Lalloo D.G., Heyderman R.S., Dandara C., Kampira E., Van Oosterhout J.J., Ssali F., Walker A.S., Novelli G., Borgiani P., Nelson M.R., Holden A., Deloukas P., Pirmohamed M. (2014). GENOME-WIDE ASSOCIATION STUDY OF NEVIRAPINE HYPERSENSITIVITY IN A MALAWIAN HIV-INFECTED POPULATION.  Carr D.F., Chaponda M., Cornejo Castro E.M., Jorgensen A.L., Khoo S.H., Van Oosterhout J.J., Lalloo D.G., Heyderman R.S., Pirmohamed M. (2014). CYP2B6*18 IS ASSOCAITED WITH NEVIRAPINE HYPERSENSITIVITY INDEPENDENTLY OF HLA-C*04:01 IN A MALAWIAN HIV POPULATION. (submitted to the Journal of Antimicrobial Chemotherapy)  
Poster presentations 
Cornejo Castro E.M., Carr D.F., Marshall V.A., Chaponda M., Lane S., Alfirevic A., Whitby D., Carrington M., Pirmohamed M.: REGULATION OF HUMAN LEUKOCYTE ANTIGEN EXPRESSION AND NEVIRAPINE-INDUCED ADVERSE DRUG REACTIONS IN A MALAWIAN HIV-POSITIVE POPULATION. EACPT, 28 - 31 August, 2013, Geneva, Switzerland  
vi 
Cornejo Castro E.M., Carr D.F., Marshall V.A., Chaponda M., Lane S., Alfirevic A., Whitby D., Carrington M., Pirmohamed M.: REGULATION OF HUMAN LEUKOCYTE ANTIGEN EXPRESSION AND NEVIRAPINE-INDUCED ADVERSE DRUG REACTIONS IN A MALAWIAN HIV-POSITIVE POPULATION. CESAR Annual Meeting, 27 - 29 June, 2013, Tuebingen, Germany  
Cornejo Castro E.M., Carr D.F., Chaponda M., Rainbow L., Lane B., Jorgensen A.L., Alfirevic A., Pirmohamed M.: INVESTIGATION OF HYPERSENSITIVITY REACTIONS TO NEVIRAPINE IN A MALAWIAN COHORT. Drug Hypersensitivity Meeting 5, 11 - 14 April, 2012, Munich, Germany  
  
  vii 
Abstract 
The non-nucleoside reverse transcriptase inhibitor nevirapine (NVP) is widely used in the treatment of human immunodeficiency virus infection in many sub-Saharan countries. However, NVP-treated individuals have a 5% risk of developing hypersensitivity reactions (HSRs), ranging from maculopapular exanthema to life-threatening severe cutaneous eruptions and hepatotoxicity. A number of clinical (gender and CD4+ T cell count) as well as immunogenetic factors (MHC class I and class II alleles) have been associated with NVP hypersensitivity, but the predictive value is poor. Gene expression analyses provide an unbiased method for determining which immune-related mechanisms are involved in the pathogenesis of NVP hypersensitivity. mRNA microarray analysis demonstrated that expression of 
CD177, a neutrophil specific antigen, was significantly increased in our cohort of NVP-treated	  patients	  from	  Malawi	  (p	  ≤	  0.001),	  but	  also	  after	   in vitro treatment of NVP-hypersensitive patients from Liverpool (p < 0.05). Interestingly, CD177 protein expression did not increase in patient samples treated with NVP in vitro. A case-control study (n = 288) of NVP-hypersensitive and tolerant patients showed that none of the investigated CD177 polymorphisms were associated with NVP-induced HSRs. Of the clinical factors analysed, only CD4+ T cell count was significantly associated with NVP hypersensitivity (p < 0.001). The polymorphisms rs45441892 and rs10425385 in CD177 have previously been associated with an increased proportion of CD177-positive granulocytes. We confirmed these results in our NVP-naïve, healthy volunteer cohort (n = 35) for rs10425385, but not rs45441892. Previous reports have identified HLA-C*04:01 as a susceptibility marker for NVP-induced HSRs in patients from Malawi. Expression levels of miR-148a, a microRNA known to downregulate HLA-C expression, were analysed in serum samples from NVP-hypersensitive and tolerant individuals (n = 96). However, paradoxically, a statistically significant increase in miR-148a expression was found in NVP-hypersensitive patients at the time of reaction (p = 0.008). Additionally, the serum expression levels of 84 miRNAs were analysed in hypersensitive and tolerant patients treated with NVP (n = 24). Twenty-one miRNAs were differentially expressed in tolerant and hypersensitive samples. Of these miRNAs, miR-205 showed the highest increase in NVP-hypersensitive patients (p < 0.01). Besides HLA-C*04, several other HLA-alleles have been reported as risk factors for NVP hypersensitivity. A summary meta-analysis of published data indicated that four HLA-allelotypes (HLA-B*35, -B*58:01, -C*04, -DRB1*01) might be common risk factors of NVP-induced HSRs for different ethnicities. The results presented in this thesis highlight that various genetic, immunological and clinical factors may contribute to the pathogenesis of NVP hypersensitivity. Further understanding of the complex interactions may ultimately lead to the characterisation of true causative associations facilitating the precise prediction of hypersensitivity reactions to NVP.   
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1.1 Drug-induced hypersensitivity reactions In the UK, drug-related adverse effects account for 6.5% of hospital admissions (PIRMOHAMED et al., 2004), while in the US adverse drug reactions (ADRs) represent the sixth leading cause of death (LAZAROU et al., 1998). It has been estimated that genetic variations can contribute 20-50% to the interindividual variability in drug response and safety. Pharmacogenetics and pharmacogenomics aim to	   optimise	   drug	   therapy	   based	   on	   each	   individual’s	  genetic profile and thus decrease the likelihood of adverse effects (EVANS and MCLEOD, 2003).  
1.1.1 Definitions of adverse drug reactions The World Health Organization (WHO) first defined an ADR as “a	  response	  to	  a	  drug that is noxious and unintended and occurs at doses normally used in man for the prophylaxis, diagnosis or therapy of disease, or for modification of physiological function”	  (WHO, 1972). In 2000, Edwards and Aronson suggested a more extensive definition:	   “An	  appreciably harmful or unpleasant reaction, resulting from an intervention related to the use of a medicinal product, which predicts hazard from future administration and warrants prevention or specific treatment, or alteration of 
the	   dosage	   regimen,	   or	   withdrawal	   of	   the	   product” (EDWARDS and ARONSON, 2000). The European Parliament and Council of the European Union proposed in 2010 to amend the definition of ADRs “to	   ensure	   that	   it	   covers	   noxious and unintended effects resulting not only from the authorised use of a medicinal product at normal doses, but also from medication errors and uses outside the terms of the marketing authorisation, including the misuse and abuse of the 
medicinal	  product”	  (EU, 2010). Though all definitions mentioned above are suitable for describing an ADR, the latter two address more specifically serious, life-threatening conditions along with reactions caused by prescription errors and off-label use. 
Chapter 1 
6 
1.1.2 Classification of adverse drug reactions Adverse drug reactions were first divided into dose-dependent (type A) and non-dose-dependent (type B) reactions (RAWLINGS and THOMPSON, 1977): 
Type A reactions represent the most common type of ADRs. They are based on the known pharmacological function of the drug. Although their severity can range from mild to serious reactions, they are characterised by a low morbidity and mortality rate (EDWARDS and ARONSON, 2000; PIRMOHAMED 
et al., 2004; UETRECHT, 2007). Age, drug-drug interactions, variations in pharmacokinetic and pharmacodynamic parameters as well as environmental factors may increase the chance of developing this type of ADR (MEYER, 2000). Examples of type A reactions include an increase in the bleeding risk with warfarin as well as hypotension caused by antihypertensives. 
Type B reactions affect only a small proportion of patients and are unpredictable, as they do not relate to the pharmacological function of the drug. They generally comprise more severe reactions and are a leading cause of drug withdrawal during drug-development. Type B reactions are often also known as idiosyncratic drug reactions (PHILLIPS and MALLAL, 2010; PIRMOHAMED et al., 1998; UETRECHT and NAISBITT, 2013). They will be further discussed in chapter 1.1.3. Later, four additional reaction types (type C-F) were proposed to account for ADRs not covered by the categories mentioned above (EDWARDS and ARONSON, 2000). In addition, Aronson et al. suggested a classification system based upon Dose dependency, Timing and individual Susceptibility [DoTS (ARONSON and FERNER, 2003)].  
1.1.3 Characteristics of idiosyncratic adverse drug reactions Type B or idiosyncratic adverse drug reactions only occur in susceptible individuals. They are characterised by a delayed onset of symptoms varying from a few minutes to multiple hours or days after drug exposure. Further, 
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adverse drug effects manifest quicker if patients, who have previously been exposed to a specific drug, are rechallenged (PIRMOHAMED, 2010; UETRECHT and NAISBITT, 2013). Another characteristic is that these reactions do not show a simple dose-response relationship, i.e. the risk does not increase proportionally with an increase in dose (UETRECHT, 2007). Idiosyncratic reactions can be further subdivided into immune-mediated and non-immune-mediated reactions. The terms immune-mediated and hypersensitive are often used interchangeably, and in this thesis the term hypersensitivity reactions (HSRs) will be used throughout. Gell and Coombs first classified HSRs into four groups based on the underlying immune mechanism (GELL and COOMBS, 1968). This classification system is summarised in figure 1.1 and includes antibody mediated reactions type I – type III as well as the T cell mediated type IV. More recently, type IV reactions have been further subdivided based on the effector cells and mediators involved in the immune response [type IVa – IVd (PICHLER, 2003)]. However, this classification represents a very simplified representation of the complex developments occurring within the immune system and often multiple reaction types can be observed simultaneously (PICHLER et al., 2010). Several demographic and clinical factors, such as age, gender, concomitant diseases, co-medication and genetic polymorphisms are known to predispose to ADRs (BECQUEMONT, 2009).  
  
8 
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1.1.4 Clinical features of idiosyncratic drug reactions Idiosyncratic drug reactions can affect almost any organ system in the human body. Each drug is associated with its own specific range of reactions, affecting single organs or multiple organ systems. However, the clinical manifestations caused by a drug may vary between patients (PHILLIPS and MALLAL, 2010; UETRECHT and NAISBITT, 2013). 
 
Drug hypersensitivity in the skin Skin reactions are the most common type of hypersensitivity reactions, with maculopapular exanthema (MPE) accounting for 90% of cutaneous ADRs [cADRs (BIGBY, 2001; HUNZIKER et al., 1997)]. These reactions appear first as isolated patches and lesions, which then spread in a symmetrical fashion to the extremities. They appear 1–2 weeks after first drug administration and symptoms usually resolve following drug withdrawal (ROUJEAU, 2005). A more severe reaction of drug-induced hypersensitivity, which involves multiple organs and white blood cell abnormalities, is drug reaction with eosinophilia and systemic symptoms (DRESS). Other terms commonly used to refer to the same syndrome are drug-induced hypersensitivity syndrome (DIHS) and hypersensitivity syndrome (HSS). DRESS is often characterised by an acute onset of rash, fever as well as hematologic defects and may include one or more of the following symptoms: lymphadenopathy, carditis, pneumonitis, hepatitis and nephritis (ROUJEAU, 2005; UETRECHT and NAISBITT, 2013). Hepatitis is the most common organ manifestation, with liver failure being the prevalent cause of mortality [mortality rate approximately 10% (HAUSMANN et al., 2010; PHILLIPS and MALLAL, 2010)]. These reactions begin 2-6 weeks after treatment initiation. Reactivation of herpes virus infections (such as human herpes virus 6 (HHV-6) and HHV-7, cytomegalovirus and Epstein-Barr virus) has been associated with DRESS (DESCAMPS et al., 1997; KOMURA et al., 2005; SEISHIMA et al., 2006; SUZUKI et 
al., 1998). This association is not completely understood; Picard et al. proposed that virus reactivation may act as a pathogenic mechanism of DRESS in which drug administration triggers virus reactivation and subsequently leads to the 
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activation of virus-specific T cells, which wrongly attack non-specific tissues (PICARD et al., 2010). Drugs most commonly associated with DRESS are anticonvulsants (e.g. carbamazepine (CBZ)), sulfonamides, allopurinol and antiretrovirals (e.g. abacavir (ABC) and nevirapine (NVP)). The most severe cADRs are Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). They are now considered to be different severity variants of the same disease, distinguished by the extent of skin detachment: SJS involves less than 10% of the body surface area, TEN more than 30% and the SJS/TEN overlapping syndrome affects 10-30%. The symptoms emerge 1-3 weeks after first drug treatment and normally begin with a sudden onset of fever and malaise, followed by a painful rash and the formation of blisters. At least two mucous membranes are usually involved and ocular symptoms develop occasionally. Histologically, SJS and TEN are characterised by extensive keratinocyte apoptosis (HAUSMANN et al., 2010; PEREIRA et al., 2007; PHILLIPS and MALLAL, 2010). This leads to separation of the dermis and epidermis, with the degree of necrosis correlating to the amount of mononuclear infiltrate in the dermis [mostly CD8+ T cells (HASHIZUME et al., 2002)]. The mortality rate reaches 10% in SJS and nearly 30% in TEN patients, with sepsis and pulmonary manifestations being the major cause of death (ROUJEAU, 2005; SVENSSON et al., 2001). Although these reactions only occur in about two patients per million each year, the incidence of SJS and TEN has been reported to be higher in human immunodeficiency virus (HIV) infected patients (MITTMANN et al., 2012; RZANY et al., 1993). At least 70% of all cases are classified as drug-induced reactions; the drugs associated with a higher risk of developing SJS/TEN are anticonvulsants (CBZ, phenytoin, phenobarbital), allopurinol and NVP (PEREIRA 
et al., 2007; ROUJEAU, 2005).  
Drug-induced liver injury Idiosyncratic drug-induced liver injury (DILI) occurs at therapeutic doses with no clear evidence of dose-dependency. The onset of DILI is variable, with reactions appearing one week to several months after first drug administration. It is further characterised by adaptation, in which mild liver injury determined 
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by elevated alanine transaminase (ALT) and aspartate aminotransferase (AST) levels, resolves in most patients despite treatment continuation (UETRECHT, 2007). Although DILI is classified as rare, occurring from 1 in 1000 to 1 in 100.000 patients, DILI is the most frequent cause for the discontinuation during drug-development and withdrawal of already established pharmaceuticals (CHALASANI and BJORNSSON, 2010; KAPLOWITZ, 2001; LEE, 2003). Drugs or their reactive metabolites have been shown to damage hepatocytes through various cellular mechanisms either by direct interaction with mitochondrial molecules, indirect increase of intracellular stress (e.g. promoting oxidative or cytoskeletal stress as well as DNA damage) or activation of the immune system through haptenization [see chapter 1.2 (KAPLOWITZ, 2004)]. Hepatocellular damage in DILI accounts for the majority of cases of acute liver injury in the US, which requires liver transplantation or results in the death of patients (KAPLOWITZ, 2005). If elevated ALT levels are accompanied by both an increase in bilirubin and the appearance of jaundice, the mortality rate increases to 10-50% (ZIMMERMAN, 1999). Recent data identified many human leukocyte antigen (HLA) alleles as genetic markers of drug-induced HSRs; the nature of these associations will be discussed in section 1.3 in more detail.  
1.2 Mechanistic hypotheses of hypersensitivity 
reactions Although the mechanisms facilitating the recognition of conventional antigens by T cell receptors (TCRs) have been explored in detail, the mechanisms by which immune-mediated ADRs elicit an immune reaction are still not clear. In general, peptides are presented on antigen-presenting cells (APCs) through major histocompatibility complex (MHC) molecules to TCRs. Thus the MHC/TCR interaction promotes an antigen-specific immune response. 
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A number of pathways that suggest how small molecules such as drugs are able to interact and activate the immune system are outlined below. These mechanisms seem to complement each other and not to occur separately.  
1.2.1 The major histocompatibility complex Originally identified in mice, HLA genes in humans encode transmembrane proteins that display endogenous and pathogen-derived peptides on the cell surface triggering a T cell mediated immune response. Located on the short arm of chromosome 6 at 6p21.3, the MHC complex contains more than 200 genes, many of which possess a function in innate and adaptive immunity. Combinations of HLA-genes feature a high level of linkage disequilibrium (LD), leading to alleles in adjacent loci to be inherited as haplotypes (STENZEL et al., 2004).  
MHC classification and structure The polygenic MHC molecules can be categorised into MHC class I and MHC class II molecules. All MHC genes are co-dominantly expressed on the cell surface. The three classical MHC I loci, HLA-A, -B and -C, as well as the three classical MHC II loci, HLA-DR, -DQ and -DP belong to the most highly polymorphic genes present in the human genome (MURPHY et al., 2012). The class I genes code for the polymorphic	   α	   heavy	   chain	   consisting	   of	   three	  
extracellular	   domains	   (α1,	   α2	   and	   α3), which is expressed in non-covalent 
association	  with	   the	   invariant	   light	   chain	  β2-microglobulin	   (β2m), encoded on chromosome 15. The peptide-binding	   groove	   is	   composed	   of	   the	   α1 and	   α2	  subdomains. In addition to the peptide binding domain and the immunoglobulin 
like	   domain	   (α3),	  MHC	   class	   I	  molecules	   possess	   a	   transmembrane	   region	   as	  well as a cytoplasmatic tail. HLA class I receptors are expressed on almost every nucleated cell, although expression levels may vary between alleles. By contrast, MHC class II molecules are expressed by APCs such as dendritic cells, B cells and macrophages only. The HLA class II genes code for two 
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polymorphic chains α	  and	  β, that contain a peptide-binding domain	  (α1	  or	  β1),	  
an	  immunoglobulin	  like	  domain	  (α2	  or	  β2)	  as	  well	  as	  a	  transmembrane	  region	  and a cytoplasmatic tail [figure 1.2 A (BHARADWAJ et al., 2012; KLEIN and SATO, 2000)]. HLA-alleles can differ by 1 to 30 amino acid residues and these polymorphisms result mainly in amino acid changes involved in peptide recognition and binding. The nomenclature of HLA-alleles was initially based on serological typing. However, the use of genotyping methods led to an increase in the number of known alleles and the introduction of an eight-digit system, which allows HLA-alleles to be differentiated [figure 1.2 B (MARSH et al., 2010; TURNER, 2004)]. MHC class I molecules that bind to identical peptides have been organised in supertypes (SETTE and SIDNEY, 1998).  
Fig. 1.2: Structure and 
nomenclature of HLA class 
I and class II molecules 
(A) MHC   class   I:   α   chain,  
consisting of two peptide-
binding   domains   (α1   and   α2)  
and an immunoglobulin like 
domain   (α3);   the   beta2-
microglubulin   (β2m)   is   the   light  
chain of the molecule. MHC 
Class   II:   α   and   β   chains   have   a  
peptide-binding   domain   (α1   or  
β1) as well as an 
immunoglobulin like domain 
(α2   or   β2).   Both   molecules  
feature a transmembrane 
domain (TM) and a 
cytoplasmatic tail (adapted 
from: KLEIN and SATO, 2000). (B) 
Nomenclature of HLA-alleles 
(adapted from: ROBINSON et al., 
2011). 
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Antigen presentation and T cell interaction Cytosolic proteins are degraded by the proteasomes and the emerging peptides are either processed into amino acids directly in the cytosol or transferred into the endoplasmic reticulum (ER). Within the ER, peptides bind to MHC class I molecules and the MHC/peptide complex is then transported via vesicles to the cell surface. The antigen presentation by MHC class II requires exogenous proteins to be endocytosed. Vesicles carrying fully assembled class II molecules merge with endosomes forming the MHC class II compartment where peptides derived from exogenous proteins are loaded into the binding groove. The loaded class II molecule is then transported to the cell surface (KLEIN and SATO, 2000; MURPHY et al., 2012). Although the MHC class I and class II pathways have been described to bind exclusively to intracellular or extracellular proteins, it has been shown that cross-presentation allows class I molecules to be loaded with exogenous peptides internalised through phagocytosis (JOFFRE et al., 2012). At the same time, fusion of autophagosomes with MHC class II compartments leads to the loading of intracellular antigens onto MHC class II molecules (MUNZ, 2012). The closed conformation of the MHC class I peptide binding groove accommodates shorter peptides than the open-ended class II groove (8–9 amino acids versus 12-25). The specificity of antigens capable of binding to a particular MHC allele is defined by a small number of amino acid residues that interact with so-called pockets in the peptide-binding groove. The cell surface is the site of the interaction between the MHC/peptide complex and the TCR. Mature T cells are differentiated by the expression of either CD4 or CD8 co-receptors, resulting in CD4+ and CD8+ T cell subtypes, which interact with MHC class II and MHC class I molecules respectively. While the TCR binds to the groove and the peptide directly, CD4 and CD8 co-receptors engage MHC molecules outside the peptide-binding groove. The interaction of the TCR with the MHC/peptide complex stimulates the antigen-specific proliferation and differentiation of the T cell. CD8+ T cells differentiate into cytotoxic T cells, whereas CD4+ T cells differentiate into T helper cells (ALBERTS et al., 2008; BHARADWAJ et al., 2012; KLEIN and SATO, 2000). 
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1.2.2 Hapten hypothesis Based on the observations from Landsteiner et al., the hapten hypothesis explains how low-molecular weight compounds that are not able to initiate T cell activation, become antigenic after covalent binding to proteins (LANDSTEINER and JACOBS, 1935; UETRECHT, 2008). Drug-protein conjugates, also known as haptens, are small chemically reactive molecules that are able to bind covalently to any kind of endogenous protein or peptide (intracellular, membrane bound or soluble). Theoretically, the type, location and amount of modified peptides may activate distinct immunological pathways leading to the diverse clinical manifestations of HSRs. Most drugs do not exhibit chemical reactive qualities, but form reactive products upon metabolism. This is called the pro-hapten concept (ADAM et al., 2011; LI and UETRECHT, 2010; PICHLER et al., 2006). For the initiation of a T cell dependent immune response, small molecules or drugs as well as their reactive metabolites must bind covalently to endogenous proteins, forming drug-protein adducts. These adducts are endocytosed and processed by APCs which then display the drug-modified peptides through MHC molecules. Once the peptide/MHC complex is recognised by the TCR, naïve T helper cells differentiate into TH1 and TH2 effector cells. The recognition of these modified adducts by TCRs is referred to as signal 1 [figure 1.3 A (PICHLER et al., 2006; PIRMOHAMED et al., 2002; UETRECHT, 2007)]. Effector cells induce a phagocyte-dependent inflammation by activating cytotoxic T cells and macrophages but can also stimulate B cell dependent antibody generation and secretion (ALBERTS et al., 2008).  
1.2.2 Danger hypothesis Drug haptenation occurs frequently after bioactivation, yet only a small number of patients are susceptible for drug-induced HSRs. This specificity is further addressed by the danger hypothesis. As the first immunological hypothesis to address the specificity of the immune system, the self-nonself model by Burnet et al. describes how naturally 
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generated peptides are tolerated by the immune system and only foreign proteins generate an immune response (BURNET, 1961). Matzinger et al. questioned this concept; she proposed that in the absence of an adjuvant, nonself proteins could not generate an immune response (MATZINGER, 1994). Prior to the interaction of the MHC/TCR complex, APCs have to be activated by a so-called danger signal (figure 1.3 B). This signal is generated through cell damage and includes a range of different molecules like cytokines, heat shock proteins and annexins. The activation of APCs leads to the upregulation of co-stimulatory molecules, mainly B7. The interaction between B7 and CD28 on the T cell membrane is referred to as signal 2 (LI and UETRECHT, 2010; UETRECHT, 2007). Without the co-stimulatory signal, the MHC/TCR interaction alone results in immune tolerance. In drug-induced HSRs cell damage induced by the formation of reactive metabolites and drug-protein conjugates may represent the danger signal. Simultaneously, these molecules can act as antigens in MHC/TCR signalling, providing the required signals to initiate an immune response (PIRMOHAMED et 
al., 2002). Other factors, such as different kinds of tissue injury, inflammation and concomitant viral infections, have been shown to increase the risk of HSRs (PIRMOHAMED, 2007; PIRMOHAMED et al., 2002).   
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Fig. 1.3: The hapten and danger hypotheses 
(A) Hapten hypothesis. Covalent binding of drugs or their reactive metabolites to endogenous 
proteins leads to the formation of drug-protein conjugates, also known as haptens. These are 
processed by APCs leading to the MHC presentation of the antigen. The recognition of the 
haptenated peptides by TCRs (signal 1) promotes cell-activation and differentiation of effector cells 
that induce a cell dependent or antigen-mediated immune response. (B) Danger hypothesis: In 
addition to signal 1, the co-stimulation of T helper cells through the interaction of CD28 with the B7 
molecule on the APC (signal 2) is required for an immune reaction. Drugs, inflammation or infection 
lead to cell damage and cytokine release (danger signal), which activate APCs and leads to the 
upregulation of the co-stimulatory molecule B7 (Adapted from: KAPLOWITZ, 2005). APC antigen 
presenting cell, MHC major histocompatibility complex, TCR T cell receptor   
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1.2.3 Pharmacological interaction (p-i) concept In 2002, Pichler et al. first suggested that drugs elicit an immune reaction by binding reversibly to certain MHC or TCR molecules [figure 1.4 (PICHLER, 2002)]. This hypothesis	  is	  known	  as	  ‘pharmacological	  interaction	  of	  drugs	  with	  immune	  
receptors’	   or	   p-i concept and is facilitated by the formation of Van der Waals and hydrogen bonds. Whether drug interaction occurs first with the MHC and is followed by the interaction of the drug-MHC complex to the TCR or whether TCRs represent the primary target for drug binding, has not been demonstrated. Pichler et al. proposed that a drug-specific activation of cross-reactive memory T helper cells allows a much faster activation of a secondary immune response, leading to an enhanced cell- or antibody-mediated immune reaction (ADAM et 
al., 2011; PICHLER et al., 2006). Like the hapten hypothesis, the p-i concept does not discuss the subject of signal 2 (UETRECHT, 2007).   
Fig. 1.4: Pharmacological interaction (p-i) 
hypothesis 
Chemical inert drugs reversibly bind to MHC or 
TCR molecules. The interaction between the 
drug-MHC complex and the TCR results in the 
activation of a secondary immune response, 
which results in a faster proliferation and 
expansion of memory T helper cells and the 
subsequent initiation of cell- or antibody-
mediated immune pathways. APC antigen 
presenting cell, MHC major histocompatibility 
complex, TCR T cell receptor       
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1.2.4 Altered HLA-peptide repertoire hypothesis Recently, a new mechanism for ABC-induced hypersensitivity has been identified [for more details see chapter 1.3.1 (ILLING et al., 2012; OSTROV et al., 2012)]. Abacavir hypersensitivity is associated with HLA-B*57:01 and T cell clones from B*57:01 positive individuals were shown to proliferate in an ABC dependent manner (CHESSMAN et al., 2008; HETHERINGTON et al., 2001). Illing et al. were able to demonstrate that ABC binds non-covalently to the HLA-B*57:01 binding grove and that this interaction consequently promotes the binding of novel peptides in the presence of the drug. Thus, the specific but reversible interaction of drugs with MHC class I molecules facilitates the binding of novel self-peptides and simultaneously prevents known peptide ligands from binding. This alteration of the peptide repertoire presented by MHC molecules leads to the activation of a distinct subset of TCRs leading to a modified immune response (figure 1.5).   
Fig. 1.5: Drug-induced 
modifications in the 
peptide repertoire 
presented by MHC 
molecules. 
The binding of novel 
peptides (peptide B) in the 
presence of the drug leads 
to the activation of distinct 
TCRs, which triggers an 
immune response (Adapted 
from: OSTROV et al., 2012). 
APC antigen presenting cell, 
TCR T cell receptor, MHC 
major histocompatibility 
complex     
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1.3 Pharmacogenetics of idiosyncratic drug reactions Genetic variations that contribute to the inter-individual variability in the efficacy and safety of therapeutics are very diverse and involve genes encoding drug-metabolising enzymes (DMEs) and drug transporters (discussed in section 1.3.2) but also immunogenic factors, which have been the main focus of HSRs [see section 1.3.3 (MA and LU, 2011)]. Besides genomic variation, individual differences in drug response may also be based on physiological and environmental factors, such as age, gender, co-existent diseases, smoking and alcohol abuse.  
1.3.1 Drug metabolism The metabolism of xenobiotics is the main elimination pathway of toxins, carcinogens and pharmaceutical molecules. Taken together absorption, distribution, metabolism and excretion (ADME) of compounds determines their bioavailability, and their efficacy and safety. Specialised enzymes, also called DMEs, facilitate the metabolism or biotransformation of substances and are divided into two categories: Phase I and Phase II [summarised in table 1.2 (WILLIAMS, 1959)]. First introduced in 1992, the elimination of detoxification products by drug transporter proteins has been categorised as Phase III metabolism (ISHIKAWA, 1992). The main site of drug metabolism is the liver, but extrahepatic tissues such as the intestine, kidney and lung feature low levels of enzymatic activity. Enzymes and transporters are also found in certain types of white blood cells (PARK et al., 1995). As will be discussed below, the majority of idiosyncratic drug reactions are mediated by the immune system. Chemically reactive metabolites may form protein adducts capable of interfering with cellular pathways and initiate a novel immune response. Thus, the formation of reactive metabolites as well as the disruption of detoxification processes followed by the formation of covalent bonds to endogenous peptides may trigger a specific immune reaction. 
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The basic principles of drug metabolism will be described below. Genetic polymorphisms altering the bioactivation of drugs may affect the predisposition of individuals to drug hypersensitivity and will therefore be discussed in chapter 1.3.3.  
Phase I reactions All reactions catalysed by DMEs result in the conversion of lipophilic drugs into more hydrophilic or polar metabolites that are easier to excrete from the body. Phase I reactions include oxidation, reduction and hydrolysis and are also classified as functionalization reactions, which unmask or introduce functional groups. One of the most common reactions is oxidation catalysed by the cytochrome P450 (CYP) enzymes. The CYP enzyme system consists of polypeptides bound to the cytoplasmatic side of the ER. It is particularly expressed in the liver but also in the lung, kidney, skin and heart. Cytochrome P450 molecules are grouped into families and subfamilies based on their sequence homology. The three main families involved in the human drug metabolism are CYP1, CYP2 and CYP3 (NEBERT et al., 1987), with the five major isoforms CYP1A2, 2C9, 2C19, 2D6 and 3A4 being responsible for the metabolism of 90% of drugs (TARANTINO et al., 2009). Additional enzymes conducting Phase I oxidation include alcohol and aldehyde dehydrogenases, Flavin-containing monooxygenases, xanthine oxidases and others (listed in table 1.2).  Depending on their chemical features metabolites that have undergone Phase I metabolism can be either excreted from the body or have to undergo Phase II biotransformation.  
Phase II reactions In Phase II, modified substrates formed in Phase I or xenobiotics that possess functional groups, are conjugated with another molecule. These reactions are catalysed by transferases; the conjugated products have increased molecular weight and their polar p
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body. Glucuronidation is the most common Phase II reaction. This reaction is facilitated by uridine disphospate glucuronosyltransferases (UGTs) that are primarily expressed in the liver, kidney and the intestine. The most important UGTs in man include UGT1A1, 1A3, 1A4, 1A6, 1A9, 2B7 and 2B15 (MINERS et al., 2006). Organ and tissue specific metabolic bioactivation of drugs may play a role in the occurrence of drug hypersensitivity. Besides detoxification, bioactivation of certain Phase I and Phase II enzyme substrates can lead to the formation of reactive metabolites that interact with endogenous polypeptides (PARK et al., 2011; SANDERSON et al., 2006). The formation of reactive metabolites in Phase I is generally catalysed by CYP enzymes, whereas conjugates of acyl glucuronides form electrophilic metabolites in Phase II (OJINGWA et al., 1994). These metabolites are able to form drug-protein adducts that either cause cell damage directly or trigger an antigen specific immune response.  
Drug transporters involved in Phase III metabolism Drug transporters can be divided into the solute carrier (SLC) transporter or adenosine triphosphate (ATP)-binding cassette (ABC) transporter superfamily. The ABC transporter family comprises primarily active transporter proteins that require ATP hydrolysis for the transport of substrates across the membrane. Expressed at the intestine and the liver, these transporters can decrease the oral bioavailability of xenobiotics and their metabolites through rapid biliary excretion (AMACHER, 2012; DIETRICH et al., 2003).   
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Table 1.1: Phase I and Phase II drug metabolising enzymes  
Pathway Enzyme Abbreviation Subcellular location 
Phase I - Oxidation 
 
Alcohol dehydrogenase  ADH Cytosol 
 
Aldehyde dehydrogenase ALDH Cytosol, mitochondria 
 
Aldehyde oxidase AO Cytosol 
 
Aldo-keto reductase AKR Cytosol 
 
Cytochrome P450 CYP ER 
 
Diamine oxidase DAO Cytosol 
 
Flavin-containing monooxygenase FMO ER 
 
Monoamine oxidase MAO Mitochondria 
 
Prostagladin H synthase PGHS ER 
 
Xanthine oxidase/ dehydrogenase XO/ XDH Cytosol 
Phase I - Hydrolysis 
 
Carboxylesterase CE ER, cytosol, lysosome 
 
Epoxide hydrolase EH ER, cytosol 
 
β-Glucuronidase Lysosomes, ER 
 
Arylesterases/ Paraoxonases PON Cytosol 
 
Pseudocholinesterase/ butyrylcholinesterase BuChE Cytosol 
 
Peptidase 
 
Lysosomes 
Phase I - Reduction 
 
Azo- and nitro-reductase ER, cytosol 
 
Carbonyl reductase Cytosol, ER 
 
Disulfide reductase Cytosol 
 
Quinone reductase NADPH Cytosol, ER 
 
Sulfoxide reductase Cytosol 
 
Reductive dehydrogenase ER 
Phase II – Conjugation 
 
Uridine disphospate glucuronyltransferase UGT ER 
 
Sulfotransferase SULT Cytosol 
 
Gluthatione S-transferase GST Cytosol, ER 
 
Amino acid conjugate system Mitochondria, ER 
 
N-Acetyltransferase NAT Cytosol 
 
Methyltransferase Cytosol, ER 
(Adapted from: KHOJASTEH, 2011)   
1.3.2 Genetic polymorphisms of drug transporters and 
metabolizing enzymes To date, many polymorphisms affecting pharmacokinetic (drug concentration) as well as pharmacodynamic (drug action) parameters have been discovered. 
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These gene polymorphisms include gene copy number variations, such as deletions or amplifications of DNA sections, as well as single-nucleotide polymorphisms (SNPs). Gene polymorphism of either Phase I or Phase II enzymes can lead to reduction, increase or the complete suppression of gene expression and enzyme activity.  Most associations of genetic polymorphisms with ADRs relate to type A reactions but a few variants of CYP isozymes, UGTs, NATs and ABC transporters have been associated with idiosyncratic ADRs and may contribute to the individual susceptibility observed (table 1.2).  
Table 1.2: Genetic polymorphisms associated with idiosyncratic hypersensitivity 
reactions 
Drug Drug class ADR Genetic variant Reference 
Phase I polymorphisms 
Clopidogrel Antiplatelet drug Cardiovascular ADRs CYP2C19 (MEGA et al., 2010) 
Codeine Opiate drug Toxic systemic ADRs CYP2D6 (GASCHE et al., 2004) 
Phase II polymorphisms 
Cisplatin Chemotherapy drug Hearing loss 
COMT 
(ROSS et al., 2009) 
TMPT 
Irinotecan Chemotherapy drug Neutropenia UGT1A1 (IYER et al., 2002) 
Sulfamethoxazole Antibiotic Hypersensitivity 
GCLC (WANG et al., 2012a) 
NAT1 (WANG et al., 2011a) 
Thiopurine Immunosuppressant Hematologic toxicity TPMT (EVANS et al., 1991) 
Tolcapone COMT inhibitor Transient ALT elevations UGT1A (ACUNA et al., 2002) 
Troglitazone Thiazolidinediones 
Hepatic failure 
(ALT/AST 
elevations) 
GSTT1 (WATANABE et al., 
2003) GSTM1 
Phase III polymorphisms 
Cyclosporine Immunosuppressant Nephrotoxicity ABCB1 (HAUSER et al., 2005) 
Statins HMG-CoA reductase inhibitor Myopathy SLCO1B1 (LINK et al., 2008) 
List of associations shows only several relevant examples (adapted from: WEI et al., 2012). ABC ATP-
binding cassette, COMT catechol-O-methyl transferase, CYP cytochrome P450 enzyme, DILI drug-
induced liver injury, GCLC glutamate cysteine ligase catalytic subunit, NSAID non-steroidal anti-
inflammatory drug, SLC solute carrier, TPMT thiopurine methyl transferase 
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1.3.3 HLA-associations and drug-induced hypersensitivity As described above, the interaction of MHC molecules and TCRs is crucial for the initiation of the adaptive immune response and the aetiology of drug-induced adverse reactions. This chapter examines the immunological background of these reactions and discusses the associations between HLA-alleles and the susceptibility to hypersensitivity. In infectious diseases, certain aspects of disease protection and susceptibility have been associated to a number of class I and class II alleles. These include the association of various HLA-alleles and the progression to acquired immunodeficiency syndrome (AIDS) in HIV-1 infected individuals; rapid progression is significantly associated with HLA class I homozygosity and the 
HLA-B*35, -C*04 alleles, whereas HLA-B*57 has been found to be negatively associated with disease progression [table 1.4 (ALTFELD et al., 2003; CARRINGTON 
et al., 1999)]. Another example is reduced susceptibility to severe malaria in sub-Saharan populations [HLA-B*53 and HLA-DRB1*13:02-DQB1*05:02 haplotype (HILL et al., 1991)]. Several studies have also identified strong links between specific HLA-alleles and hypersensitivity to various drugs, including antibiotics, antiretrovirals and non-steroidal anti-inflammatory drugs (summarised in table 1.3). Overall each drug appears to be associated with a specific set of HLA-alleles and the association is also dependent on the disease phenotype. Additionally the HLA-alleles linked to drug-induced ADRs are population-dependent, which may be based on the allele frequencies that can vary between different ethnicities. This section will discuss some of the best-defined examples of drug-induced HSRs with associations to HLA-alleles (ABC, CBZ and allopurinol). As the focus of this thesis lies on nevirapine and its ability to induce HSRs, it will be reviewed in section 1.5 in more detail; a short representation of all known HLA associations and NVP-induced hypersensitivity can be found in table 1.6 below. 
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Table 1.3: Associations of HLA class I and II alleles w
ith drug-induced hypersensitivity 
Drug 
Drug class 
HLA-allele 
Adverse reaction 
Population 
Reference 
M
HC class I associations 
Abacavir 
Antiretroviral 
B*57:01 
DRESS/DIHS/HSS 
Caucasians 
(H
ETHERIN
GTO
N et al., 2001; M
ALLAL 
et al., 2002) 
Allopurinol 
Anti gout  
B*58:01 
SJS/TEN
 
and 
DRESS/DIHS/HSS 
Han Chinese 
Koreans 
Japanese 
Thai 
Caucasians 
(H
U
N
G et al., 2005) 
(K
AN
G et al., 2011) 
(K
AN
IW
A et al., 2008) 
(TASSAN
EEYAKU
L et al., 2009) 
(LO
N
JO
U et al., 2008) 
Carbam
azepine 
Antiepileptic 
B*15:02 
SJS/TEN
 
Han Chinese 
Thai 
M
alay 
Indian 
(C
HU
N
G et al., 2004) 
(TASSAN
EEYAKU
L et al., 2010) 
(C
HAN
G et al., 2011) 
(M
EHTA et al., 2009) 
A*31:01 
DRESS/DIHS/HSS 
Japanese 
Caucasians 
(O
ZEKI et al., 2011) 
(M
CC
O
RM
ACK et al., 2011) 
Feprazone 
Analgesic 
B22 
Fixed-drug eruption 
Italian 
(P
ELLICAN
O et al., 1997) 
Flucloxacillin 
Antibiotic 
B*57:01 
DILI 
Caucasians 
(D
ALY et al., 2009) 
Levam
isole 
Anthelm
inthic 
B*27 
Agranulocytosis 
South Am
erican 
(D
IEZ, 1990) 
O
xicam
 
N
SAID 
A*2, B*12 
SJS/TEN
 
Caucasians 
(R
O
U
JEAU et al., 1987) 
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Abacavir hypersensitivity syndrome and HLA-B*57:01 Abacavir is a NRTI used in combination therapies for HIV-1 infections since 1999 (see section 1.3). Hypersensitivity to ABC occurs in approximately 5-8% of patients initiating treatment and is characterised by at least two of the following symptoms: rash, fever, nausea and gastrointestinal or respiratory symptoms. Reactions develop within six weeks after exposure and resolve upon withdrawal of the drug; rechallenge of patients however leads to the occurrence of more severe, life threatening reactions (CUTRELL et al., 2004; HETHERINGTON et 
al., 2001). The presence of CD8+ T cells in the skin of patients with ABC-induced rash implies that the pathogenic mechanism of ABC-induced HSRs are immune mediated (PHILLIPS et al., 2002). In 2002, two independent studies identified a strong association between ABC hypersensitivity and the MCH class I allele HLA-B*57:01 (HETHERINGTON et al., 2002; MALLAL et al., 2002). Clinical over-diagnosis of ABC HSRs and ethnic variations in the B*57:01 carriage frequency contributed to a low sensitivity of 
HLA-B*57:01 screening for ABC-induced ADRs. Later, diagnosis of true immunologically mediated ABC hypersensitivity was improved through the introduction of patch testing and allowed clinical studies to evaluate the sensitivity of HLA-genotyping more clearly (HUGHES et al., 2004; PHILLIPS et al., 2002). The randomized double-blind controlled trial PREDICT-1 and the SHAPE case-control study demonstrated a negative predictive value of 100% and a positive predictive value of 47.9% of HLA-B*57:01 for ABC hypersensitivity across various populations (MALLAL et al., 2008). In response to these findings, which have subsequently been validated by a number of independent studies (RAUCH et al., 2006; YOUNG et al., 2008; ZUCMAN et al., 2007), HLA-B*57:01 screening is now mandated by the US Food and Drug Administration (FDA) prior to ABC prescription (FDA, 2008). Thus, the introduction of HLA-B*57:01 genotyping into clinical practice reduced not only the incidence of ABC hypersensitivity from approximately 5-8% to < 1%, but also the number of cases of unnecessary withdrawal of ABC treatment [from 8% prior to screening to < 3% (BANNISTER et al., 2008; RAUCH et al., 2006; WATERS et al., 2007; ZUCMAN 
et al., 2007)]. 
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Fifty per cent of HLA-B*57:01 positive patients tolerate ABC treatment, thereby indicating that other factors such as genetic or environmental aspects, must affect the occurrence of ABC-induced hypersensitivity. The potential for inducing a CD8+ T cell mediated immune response in HIV-negative, HLA-
B*57:01 positive healthy volunteers argues against a contribution of HIV infection to the development of ABC-induced HSRs (CHESSMAN et al., 2008). Further studies are needed to elucidate the contribution of different TCRs and regulatory T cell types toward the individual susceptibility of ABC-treated patients. Several groups have shown that activation of ABC-specific T cells is dependent on the formation of direct bonds between ABC an endogenous MHC molecules (ILLING et al., 2012; NORCROSS et al., 2012; OSTROV et al., 2012). As such, ABC binding changes the conformation of the MHC binding groove and alters the peptides loaded onto HLA-B*57:01. A differentiated T cell response is then triggered by the presentation of novel self-peptides through the ABC-modified MHC peptide complex.  
Carbamazepine hypersensitivity and HLA-B*15:02 or HLA-A*31:01 Carbamazepine is an aromatic amine anticonvulsant primarily used in the treatment of epilepsy, bipolar disorders and trigeminal neuralgia that causes several different types of cADRs, including the life threatening reactions SJS and TEN. These reactions are characterised by severe epithelial cell apoptosis on epidermal and mucosal membranes, occurring within two months of treatment initiation. Despite being relatively rare in Europeans (one to six in 10.000 patients), the prevalence of CBZ-induced SJS/TEN is significantly higher in Chinese and Southeast Asians (CHUNG et al., 2004; PHILLIPS and MALLAL, 2010). The first study to report a strong association between HLA-B*15:02 and CBZ-induced SJS/TEN in Han Chinese was published in 2004 (CHUNG et al., 2004). All patients with CBZ-induced SJS/TEN were carriers of HLA-B*15:02, but only 3% of CBZ-tolerant, and 8.6% of the population controls were positive for the allele. This association has since been replicated not only in Han Chinese (MAN et al., 2007; WANG et al., 2011b; WU et al., 2010; ZHANG et al., 2011b), but also in Thai, 
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Malay and Indian populations (CHANG et al., 2011; MEHTA et al., 2009; TASSANEEYAKUL et al., 2010). In CBZ-patients of Caucasian and Japanese ancestry, the association of HLA-B*15:02 and CBZ-induced SJS/TEN has not been observed (IKEDA et al., 2010; KANIWA et al., 2008; LONJOU et al., 2008). The HLA-
B*15:02 allele has a very low frequency in Caucasians and Japanese (< 0.01%) compared to people in southeast Asia, India and China explaining the high prevalence of SJS/TEN reactions in these specific populations (GONZALEZ-GALARZA et al., 2011). A meta-analysis of HLA-B*15:02 and CBZ-induced SJS/TEN in Asian patients showed that HLA-B*15:02 positive patients are over a hundred times more likely to develop SJS/TEN during CBZ-treatment [OR: 113.39; confidence interval (95% CI) 51.24 – 250.97 (YIP et al., 2012)]. In 2007, the U.S. FDA recommended HLA-B*15:02 screening for all	  Asian	  patients	  “with	  ancestry	  from areas where HLA-B*15:02 is	  present”,	  prior to CBZ-treatment (FDA, 2007). Various in vitro studies have shown that CD4+ and CD8+ T cells from patients can be stimulated by CBZ treatment and that usage of specific TCRs is important for CBZ-induced SJS/TEN in HLA-B*15:02 positive individuals (KO et al., 2011; WU et al., 2007). Additional data suggest that the activation of T cells by HLA-B*15:02 is mediated via the p-i model: the interaction of the drug with the MHC/peptide complex occurs extracellularly without the involvement of intracellular CBZ-metabolism and can be abolished by the incubation with anti-HLA-B antibodies (BHARADWAJ et al., 2012). Further, endogenous peptides loaded onto the MHC molecule were required to stabilise the MHC/peptide complex and facilitate CBZ binding. In vivo studies have shown that CD8+ T cells, able to induce keratinocyte-specific apoptosis, can be found in blister fluids of TEN patients supporting the role of T cell activation and immune response as part of the pathophysiological pathways leading to HLA-B*15:02 associated CBZ-induced SJS/TEN (NASSIF et al., 2004; NASSIF et al., 2002). Drug-induced SJS has been associated with several other aromatic amine anticonvulsants, e.g. oxcarbazepine and phenytoin (HUNG et al., 2010; MAN et al., 2007), as well as a number of different alleles that are members of the HLA-B75 serotype (IKEDA et al., 2010; KANIWA et al., 2010; KIM et al., 2011). These results indicate that the pathophysiological mechanism of SJS/TEN caused by aromatic 
Chapter 1 
 31 
amine anticonvulsants may be related to a possible cross-reactivity of these drugs and the activation of similar immunological pathways. 
HLA-A*31:01 was first reported as a possible risk allele for CBZ-induced MPE in a Han Chinese population by Hung et al. (2006). Later, carriage of HLA-A*31:01 was linked to several phenotypes of CBZ hypersensitivity, including HSS and SJS/TEN in Caucasians, Japanese and Koreans (KASHIWAGI et al., 2008; KIM et al., 2011; MCCORMACK et al., 2011; OZEKI et al., 2011). The pooled meta-analysis of reported HLA-A*31:01 associations with CBZ hypersensitivity throughout all populations generated an OR of 9.5 [95% CI 6.42 – 13.93 (YIP et al., 2012)]. The allele frequency of HLA-A*31:01 is more generally distributed with 2-7% in Han Chinese, 5% in Koreans, 7-12% in Japanese and 2-6% in western Europeans (GONZALEZ-GALARZA et al., 2011). Whereas the pathogenic mechanism of CBZ-induced SJS/TEN and HLA-B*15:02 associations has been carefully investigated, nothing is known about the mechanism underlying HLA-A*31:01 associated HSRs. The contribution of other genetic and environmental factors to the development of CBZ-induced HSRs cannot be excluded as HLA-B*15:02 and HLA-A*31:01 are not required nor sufficient for the development of HSRs and many patients carrying these alleles tolerate treatment with CBZ and other aromatic amine anticonvulsants.  
Allopurinol-induced hypersensitivity and HLA-B*58:01 Allopurinol is a xanthine oxidase inhibitor known to cause cutaneous ADRs in 2% of patients (ARELLANO and SACRISTAN, 1993). First published in 2005 in a Han Chinese population from Taiwan (HUNG et al., 2005), the strong association between allopurinol hypersensitivity and the HLA-B*58:01 allele has since been replicated in Thai (TASSANEEYAKUL et al., 2009) and Koreans (KANG et al., 2011). In Japanese (DAINICHI et al., 2007; KANIWA et al., 2008) and Caucasians (LONJOU et 
al., 2008) the association between HLA-B*58:01 and allopurinol-induced ADRs is weaker than in the Southeast Asian populations, suggesting that the strength of the association may be connected to the HLA-allele frequencies in the different populations. The frequency of HLA-B*58:01 is 2-11% in Han Chinese, 
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6-9% in Thai and 7% in Koreans whereas it is low in Caucasians (1-6%) and Japanese [0.5% (GONZALEZ-GALARZA et al., 2011)]. As stated previously, HLA-B*58:01 positive tolerant patients indicate that the presence of HLA-B*58:01 is not sufficient for the occurrence of drug-induced HSRs in allopurinol-treated patients. No data on the pathogenic mechanism involved in the development of allopurinol-induced ADRs has been published to date.  
1.4 Acquired immune deficiency syndrome AIDS is the most extreme form of immune suppression observed in humans and is caused by HIV infection. Progression to AIDS is triggered by the gradual loss of the immune system whereby HIV infected individuals become susceptible to opportunistic infections through bacteria, fungi, parasites and viruses. AIDS-associated malignancies are now recognised as the most common cause of death, as HIV infected patients have a higher risk of developing aggressive forms of Kaposi’s	   sarcoma	   as	   well	   as	   non-Hodgkin lymphoma and cervical cancer (reviewed in KALLINGS, 2008). Although first described in 1981, HIV infection was not recognised as the cause of AIDS until 1983 (BARRE-SINOUSSI et 
al., 1983; CHERMANN et al., 1983; GOTTLIEB et al., 1981). To date AIDS is epidemic, with prevalence rates as high as 18% across southern and eastern Africa. In 2012, an estimated 34 million people worldwide were HIV positive, of which 69% were living in sub-Saharan Africa. Nearly 3 million people were newly infected with HIV in 2010, although the annual incidence of HIV infections has fallen in 33 countries since 2001 (UNAIDS, 2012b; WHO, 2011).  
1.4.1 Human immunodeficiency virus 1 Two types of HIV have been identified, namely HIV-1 and HIV-2 (CLAVEL et al., 1986; REEVES and DOMS, 2002). Whereas HIV-2 infections are predominantly 
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restricted to West Africa, most occurrences of AIDS worldwide are caused by the more virulent type HIV-1 (KILMARX, 2009). Infection with HIV occurs through transmission of body fluids and is dependent on the concentration of both free virus and virus infected cells as well as the susceptibility of the host (LEVY, 1988). The most common route of infection is sexual intercourse but mother-to-child transmission (MTCT) is also observed.  
Structure and molecular features Mature HIV virions consist of a lipid bilayer membrane of host cell origin and a tetrameric envelope protein complex, encoded by the virus (see figure 1.6). The viral envelope protein complex is composed of two subunits, gp120 (or outer envelope protein) and gp41 (transmembrane protein). Like all retroviruses the lipid bilayer membrane surrounds the virus capsid, which contains the matrix protein p17, the major capsid protein p24, the nucleocapsid protein p7/p9, genomic RNA molecules and the three main viral enzymes (protease, reverse transcriptase (RT) and integrase). The HIV genome consists of two identical 9.3 kb single stranded RNA molecules coding for nine genes. The coding region is flanked by two long terminal repeats (LTRs), which can bind host transcription factors and are required for the integration of the provirus into the host DNA. The gag gene encodes the structural HIV proteins (p17, p24 and p7/p9), while protease, integrase and RT are encoded by pol. The envelope precursor protein gp160, containing the two envelope proteins gp41 and gp120, is encoded by the env gene. In addition, HIV-1 contains the accessory genes vif, vpr, rev (regulator of expression); tat (transactivator of transcription); vpu and nef (negative regulatory factor) (BARRE-SINOUSSI, 1996; SIERRA et al., 2005).   
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Fig. 1.6: Schematic 
representation of an HIV 
virion 
Viral enzymes (protease, integrase 
and RT) as well as genomic RNA 
molecules associated with NC 
proteins are enclosed in the major 
capsid protein. The lipid bilayer 
membrane includes a tetrameric 
envelope protein complex 
consistent of the gp120 and pg41 
subunits (Adapted from: BARRE-
SINOUSSI, 1996; MURPHY et al., 
2012). CA capsid protein, MA 
matrix protein, NC nucleocapsid 
protein, RT reverse transcriptase    
Replication cycle of HIV-1 HIV infection begins with the binding of the virus to the cell surface (figure 1.7). This is facilitated by the interaction of the HIV-1 gp120 with the cellular receptor CD4, which leads to the conformational change in gp120 uncovering a co-receptor binding site (SATTENTAU and MOORE, 1993; YOON et al., 2010). The chemokine receptors CCR5 and CXCR4 are the main HIV co-receptors promoting fusion and entry to the host cell. R5 virus strains use the CCR5 for entry to macrophages, whereas X4 viruses use the CXCR4 receptor for infection of T cells [M- and T-tropic viruses (LEVY, 1988; MURAKAMI and YAMAMOTO, 2010)]. Binding to the co-receptors leads to the fusion of the viral and cellular membranes releasing the viral core into the cytoplasm. Once uncoating of the virion core is completed the reverse transcription complex (consisting of the viral RNA, RT, integrase and several other viral proteins as well as a multitude of host proteins) is formed (FREED, 2001; SIERRA 
et al., 2005). Within this complex, the viral RNA is retro-transcribed into double-stranded DNA and upon its completion the HIV provirus translocates to the nucleus. Integration of the provirus into the host genome is mediated by the viral integrase. The initiation of viral transcription leads to the production of multi-spliced transcripts of Nef, Tat and Rev through the activation of the LTR 
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promoter by the nuclear transcription factor κB	  (NF-κB). Tat controls efficient RNA-polymerase II (Pol II) elongation of viral transcription, while Ref promotes the transport of viral mRNA molecules into the cytosol. The viral protein Nef alters endosome trafficking thus reducing the cell surface expression of CD4 and MHC molecules (particularly HLA-A and HLA-B expression) and providing protection against immune-mediated cell death. Following the expression of Tat, Rev and Nef, single-spliced and unspliced mRNA molecules are expressed and transported out of the nucleus. The incorporation of both, the gp41 and gp120 precursor protein gp160 as well as Gag polyprotein into the cellular membrane leads to the initiation of HIV assembly. A ribosomal frameshift leads to the translation of the Gag-Pol polyprotein that includes the viral enzymes, such as protease, integrase and RT. The assembly of the immature virion core is completed once the genomic RNA, enzymes and structural proteins associate at the host membrane. Fusion of the cellular membrane around the core completes the budding process. During virus maturation, the protease auto-catalytically cleaves the Gag-Pol polyproteins, releasing the viral enzymes into the core (FREED, 2001; SIERRA et al., 2005; TRKOLA, 2004).  
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Fig. 1.7: HIV-1 replication cycle and targets of antiretrovirals 
Binding of HIV virion to CD4 receptor and CCR5 or CXCR4 co-receptor promotes membrane fusion 
and entry of the virion core into the host cell. Following uncoating, reverse transcription of the viral 
genomic RNA is initiated and the provirus translocates towards the nucleus. Integration of the 
provirus into the host genome induces the production of viral messenger RNAs. The viral proteins 
Tat, Nef and Rev are translated from multi-spliced mRNA molecules. Single-spliced mRNA molecules 
are translated into envelope proteins, whereas full-length mRNAs provide new viral genomic RNA as 
well as templates for the core proteins. Viral core proteins and enzyme precursors assemble at the 
host cell membrane forming the immature virion core. Subsequently immature virions are released 
from the cells and the processing of precursor proteins by the viral protease initiates virus 
maturation. The molecular targets of antiretroviral therapy are indicated in red (adapted from: 
BARRE-SINOUSSI, 1996). NRTI nucleoside and nucleotide reverse transcriptase inhibitor, NNRTI non-
nucleoside reverse transcriptase inhibitor   
Immune response in HIV-1 infection HIV infection can be divided into three stages: the acute or primary infection is characterised by influenza-like symptoms, increase in viremia and loss of CD4+ T cells. It occurs two to four weeks after infection and the initiation of an HIV-specific cellular immune response leads to HIV antibody production, known as seroconversion and a decline in the plasma viral load. During the clinical 
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asymptomatic stage, which can last for about ten years, people remain infectious and persistent HIV replication in the lymph nodes leads progressively to a loss of CD4+ T cells. Once the decline in CD4+ T cells reaches a critical point (< 200 cells/µl) and cell-mediated immunity is lost, the occurrence of opportunistic infections increases, which indicates the progression from HIV infection to AIDS. The cellular immune response during primary infection is characterised by the activation of cytotoxic CD8+ T cells (CTLs) prior to seroconversion. Recognition of HIV infected cells requires the interaction of MHC molecules associated with viral peptides and the TCR, which leads to the lysis of infected cells. Besides the CTL mediated killing of HIV infected cells, binding of CTLs induces the release of chemokines that are endogenous ligands to the CCR5 co-receptor and inhibit CCR5 mediated fusion of the virus and the CD4+ T cell membrane. Neutralizing antibodies targeted against the extracellular domains gp120 and gp41 mediate the phagocytosis of virions as part of humoral immunity. However both, the cellular as well as the humoral immune responses are unable to eradicate the virus and clear the infection. This is favoured by high mutation rates of HIV-1, which allows the virus to escape CTL recognition through mutations within viral antigens and overcome the antiviral activity of neutralising antibodies trough conformational changes of mutated gp120 molecules (reviewed in: MURPHY et al., 2012; SIERRA et al., 2005).  
Immune control of HIV-1 infection by the host Untreated HIV-1 infected individuals have shown differences in disease outcome, with the majority of patients progressing to AIDS in less than a year. Nevertheless, approximately 5% of infected individuals (also called long term nonprogressors) sustain normal CD4+ T cell counts and low virus titres for decades (CAO et al., 1995). Patients who sustain undetectable HIV plasma viral load for longer than ten years represent less than 1% of HIV infected individuals and are known as elite controllers or HIV controllers (SAEZ-CIRION et al., 2007). 
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Long-term survival without antiretroviral therapy (ART) is determined by the following factors (LEVY, 2009; SAEZ-CIRION et al., 2007):  (a) mutations in the infecting virus strain itself (e.g. lack of Nef); (b) strong T cell mediated immune response and high amount of neutralising antibodies; (c) the immunogenic background of the host (discussed below). A deletion of 32 base pairs (bp) in the gene encoding the CCR5 co-receptor 
(CCR5Δ32) leads to the formation of a truncated protein (DEAN et al., 1996). This protein, which is not expressed on the cell surface, has been shown to actively downregulate CXCR4 expression and individuals homozygous for the mutant 
CCR5Δ32	   allele	   are	   highly	   resistant	   against	   HIV-1 infection (AGRAWAL et al., 2007; AGRAWAL et al., 2004). In heterozygous patients, progression to AIDS is delayed (MEYER et al., 1997; O'BRIEN and MOORE, 2000).	  The	  CCR5Δ32	  mediated	  protection is not absolute: homozygous	  CCR5Δ32 individuals can be infected by the X4 virus strain, leading to a persistent HIV-1 infection (O'BRIEN et al., 1997; SHEPPARD et al., 2002). As described above, a number of HLA-alleles have been associated with protective effects or higher susceptibility in infectious diseases (see table 1.4). Recently these associations were replicated in a multinational consortium, which established that immunogenic control of HIV-1 by the host was due to specific amino acids of the HLA-B binding groove. Changes of these key residues may affect HLA-allele specific binding properties and MHC mediated peptide presentation in HIV infected cells. Also variation in HLA-C expression (associated with the SNP rs9264942) may affect the host response to HIV (INTERNATIONAL HIV CONTROLLERS STUDY et al., 2010).    
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Table 1.4: Most consistent associations of HLA-alleles and HIV-1 progression 
 
HLA locus Reference 
Rapid progression to AIDS 
 
MHC class I homozygosity 
(One gene locus) 
(CARRINGTON et al., 1999; TANG et al., 1999) 
 
 
HLA-B*35 (CARRINGTON et al., 1999; ITESCU et al., 1992) 
Delay in AIDS progression 
 
 
HLA-B*27 (HENDEL et al., 1999; KASLOW et al., 1996) 
HLA-B*57 (COSTELLO et al., 1999; HENDEL et al., 1999; KASLOW et al., 1996)   
MicroRNA mediated regulation of HLA-C expression First described in 2009, a SNP located 35 kb upstream of the HLA-C locus was associated with the viral plasma load and HLA-C mRNA levels (INTERNATIONAL HIV CONTROLLERS STUDY et al., 2010; THOMAS et al., 2009). The -35 SNP was later shown to be in strong LD with the microRNA miR-148a binding site in the HLA-
C 3’	  untranslated	  region	  [UTR	  (KULKARNI et al., 2011)]. MicroRNAs (miRNAs) are highly conserved ~22 nucleotide-long RNA molecules known to post-transcriptionally regulate gene expression. The miR-148a mediated regulation of HLA-C surface expression is controlled by a single bp insertion/deletion of position 263 located downstream of the HLA-C stop codon (263del). This deletion lies within the miRNA-binding site and prevents miR-
148a	   binding	   to	   the	   3’	   UTR	   of	   HLA-C. Alleles that contain 263del (HLA-C*02, 
C*05, C*06, C*08, C*12, C*15 and C*16)	   are	   therefore	   termed	   “escaped	   alleles”	  whereas miR-148a restricts the expression of alleles that have an intact miR-148a binding site [“inhibited	  alleles”: HLA-C*01, C*03, C*04, C*07, C*14 and C*17 (KULKARNI et al., 2011; O'HUIGIN et al., 2011)]. Even though miR-148a has been shown to regulate HLA-C expression directly, other factors may contribute to the difference in allelic-specific expression patterns. Apps et al. have proposed that the HIV protection provided through an increase in HLA-C expression levels may be based on an intensified CTL mediated immune reaction (APPS et 
al., 2013).  
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1.4.2 Antiretroviral therapy The number of AIDS-related deaths has been declining in the past decade as ART became more widely accessible for people around the world. At present, eight million people have been reported to receive ART and also the number of HIV infected women receiving ART for the prevention of MTCT has been steadily increasing (UNAIDS, 2012b). Currently, 25 antiretroviral drugs and various fixed-dose drug combinations have been approved for the treatment of HIV infections [table 1.5 (FDA, 2013)]. Antiretrovirals are categorized according to the specific step in the HIV replication cycle targeted by the drug (see figure 1.7) and aim to reduce the plasma viral load to undetectable levels and attain a normal immunological function through increase of the CD4+ T cell count. It has been suggested that patients with symptomatic HIV disease start therapy directly, whereas asymptomatic patients should not be initiated unless their CD4+ T cell count drops below 350 cells/µl and the risk for disease progression as well as possible comorbidities have been assessed (HAMMER et al., 2008; VOLBERDING and DEEKS, 2010). Highly active antiretroviral therapy (HAART), a combination of two or three antiretrovirals, has achieved the best clinical benefits. The most common drug combinations consist of two NRTIs and either a non-nucleoside reverse transcriptase inhibitor (NNRTI), a protease inhibitor (PI) or an integrase inhibitor. The initial drug regimen may be changed if the patient experiences drug-induced ADRs or treatment fails to reduce the viral plasma load within 24 weeks of therapy (TSIBRIS and HIRSCH, 2010).  
Nucleoside and nucleotide reverse transcriptase inhibitors NRTIs were the first clinically used antiretroviral agents (YARCHOAN et al., 1986). This class of drugs act as competitive inhibitors of the viral RT by binding to its catalytic site and preventing the incorporation of endogenous deoxynucleoside triphosphates (dNTPs) into the growing proviral DNA molecule. Similar to 
dNTPs,	   NRTIs	   require	   phosphorylation	   to	   form	   the	   active	   5’-triphosphate molecule. 
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Non-nucleoside reverse transcriptase inhibitors In contrast to NRTIs, binding of NNRTIs does not occur at the active site of the viral RT but in close proximity thus disrupting the interaction of the enzyme with its normal substrate. NNRTIs are HIV-1 specific but mutations of the amino acids with which these drugs interact are known to cause resistance of the virus to one or more drugs of this class. They are primarily metabolised via the hepatic pathway and are substrates for CYP enzymes.  
Protease inhibitors PIs selectively bind to the homodimeric structure of the HIV protease and inhibit the catalytic function of the enzyme, as they cannot be proteolytically cleaved. Ritonavir is often used at sub-therapeutic doses to increase the drug concentrations of other PIs as it also inhibits CYP3A4 function.  
HIV integrase strand transfer inhibitor HIV integrase inhibitors block the integration of the viral DNA into the host genome by preventing the strand transfer reaction of the HIV-1 and HIV-2 integrase.  
Fusion and entry inhibitors Fusion and entry inhibitors prevent the binding, fusion and entry of the virion to the host cell through the interaction with the viral gp41 glycoprotein or as a CCR5 co-receptor antagonist. CCR5 antagonists are only active against the R5 virus strain and require genotypic testing of virus tropism to avoid selective replication of X4 viruses (reviewed in: DE CLERCQ, 2009; TSIBRIS and HIRSCH, 2010).   
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Table 1.5: Antiretroviral drugs approved by the U
.S. FDA 
 
Generic N
am
e 
Abbreviation 
Brand N
am
e 
M
anufacturer 
Approval Date 
N
ucleoside Reverse Transcriptase Inhibitors (N
RTIs) 
 
Abacavir 
ABC 
Ziagen 
GlaxoSm
ithKline 
17-Dec-1998 
 
Didanosine 
ddl 
Videx EC 
Bristol M
yers-Squibb 
31-O
ct-2000 
 
Videx 
9-O
ct-1991 
 
Em
tricitabine 
3TC 
Em
triva 
Gilead Sciences 
2-Jul-2003 
 
Lam
ivudine 
 
Epivir 
GlaxoSm
ithKline 
17-N
ov-1995 
 
Stavudine 
d4T 
Zerit 
Bristol M
yers-Squibb 
24-Jun-1994 
 
Tenofovir disoproxil fum
arate 
TDF 
Viread 
Gilead 
26-O
ct-2001 
 
Zidovudine 
ZDV 
Retrovir 
GlaxoSm
ithKline 
19-M
ar-1987 
N
on-N
ucleoside Reverse Transcriptase Inhibitors (N
N
RTIs) 
 
Delavirdine 
DLV 
Rescriptor 
Pfizer 
4-Apr-1997 
 
Efavirenz 
EFV 
Sustiva 
Bristol M
yers-Squibb 
17-Sep-1998 
 
Etravirine 
 
Intelence 
Tibotec Therapeutics 
18-Jan-2008 
 
N
evirapine 
N
VP 
Viram
une  
Boehringer-Ingelheim
 
21-Jun-1996 
 
Rilpivirine 
 
Edurant 
Tibotec Therapeutics 
20-M
ay-2011 
Protease inhibitors (PIs) 
 
Atazanavir sulfate 
ATV 
Reyataz 
Bristol-M
yers Squibb 
20-Jun-2003 
 
Darunavir 
 
Prezista 
Tibotec, Inc. 
23-Jun-2006 
 
Fosam
prenavir Calcium
 
FO
S-APV 
Lexiva 
GlaxoSm
ithKline 
20-O
ct-2003 
 
Indinavir 
IDV 
Crixivan 
M
erck 
13-M
ar-1996 
 
lopinavir and ritonavir 
LPV/RTV 
Kaletra 
Abbott Laboratories 
15-Sep-2000 
 
N
elfinavir m
esylate 
N
FV 
Viracept 
Agouron Pharm
aceuticals 
14-M
ar-1997 
 
Ritonavir 
RTV 
N
orvir 
Abbott Laboratories 
1-M
ar-1996 
 
Saquinavir m
esylate 
SQ
V 
Invirase 
Hoffm
ann-La Roche 
6-Dec-1995 
 
Tipranavir 
TPV 
Aptivus 
Boehringer Ingelheim
 
22-Jun-2005 
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1.5 Nevirapine In 1996, NVP [Viramune©, Boehringer-Ingelheim (figure 1.8)] became the first NNRTI approved for the treatment of HIV-1 infections. It has been shown to reduce plasma viral load effectively as part of triple combination therapy and as a single-dose treatment for the prevention of MTCT. At steady state, the therapeutic range of NVP plasma concentration covers 11-30 µM after administration of 400 mg per day (BOEHRINGER-INGELHEIM, 2012). NNRTIs bind to a hydrophobic pocket near the dNTP and NRTI binding site. This leads to conformational modifications of enzyme structure, thereby inhibiting DNA-polymerase activity (TANTILLO et al., 1994). Single bp mutations leading to amino acid changes in the binding domain, such as p.Y181C and p.K103N, reduce NNRTI-binding affinity and cause the expansion of NVP-resistant HIV-1 strains (DEEKS, 2001; RICHMAN et al., 1994). Higher plasma levels of NVP have been associated with improved HIV clearance and a decrease in the occurrence of NVP-resistance mutations (GONZALEZ DE REQUENA et al., 2005; VELDKAMP et al., 2001).  
1.5.1 Nevirapine pharmacokinetics After oral administration, NVP is almost completely absorbed in the intestine with a mean bioavailability of more than 90%. Four hours after administration, maximum NVP plasma concentration is achieved. It is distributed throughout the body with only 60% of the administered drug binding to plasma proteins. In the liver, NVP is predominantly metabolised by CYP isoenzymes 2B6 and 3A4. Multiple dosing with 200–400 mg NVP per day results in auto-induction of these enzymes and leads to an increase in plasma clearance as well as a decrease in its half-life to 30 hours (discussed in: COOPER and VAN HEESWIJK, 2007). Nevirapine is primarily excreted in urine after glucoronide conjugation via the urine (RISKA 
et al., 1999a).  
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Nevirapine metabolism In both humans and rats, NVP is metabolised into 2-hydroxynevirapine (2-OH-NVP), 3-hydroxynevirapine (3-OH-NVP), 8-hydroxynevirapine (8-OH-NVP), 12-hydroxynevirapine (12-OH-NVP) and 4-carboxynevirapine (4-COOH-NVP) (RISKA et al., 1999a; RISKA et al., 1999b). While the formation of 2-OH- and 12-OH-NVP is primarily catalysed by CYP3A4, CYP2B6 plays a role in the biotransformation of 3-OH- and 8-OH-NVP (ERICKSON et al., 1999). 12-OH-NVP is further oxidized to generate 4-COOH-NVP. Glucuronidation results in the excretion of these metabolites through the renal system. Polymorphisms in genes encoding particular NVP-metabolising enzymes have been shown to influence NVP pharmacokinetics. The CYP2B6 c.516G>T (rs3745274) polymorphism is associated with a decrease in the catalytic activity and affects NVP plasma concentrations in Black Africans (BROWN et al., 2012; CICCACCI et al., 2010; DICKINSON et al., 2013; PENZAK et al., 2007), Cambodian (CHOU et al., 2010), Indian (RAMACHANDRAN et al., 2009), Swiss (ROTGER et al., 2005) and mixed populations (HEIL et al., 2012; MAHUNGU et al., 2009; WYEN et al., 2008). Accordingly, the c.983T>C SNP (rs28399499) in 
CYP2B6, which is absent in Caucasian populations, has been associated with differences in NVP plasma levels (DICKINSON et al., 2013; WYEN et al., 2008). Recently, a SNP (rs2125739) in the ABCC11 efflux transporter was independently associated with NVP plasma concentrations (LIPTROTT et al., 2012). Other factors that influence NVP plasma levels are ethnicity, gender, weight, concomitant hepatic disease and co-medication (HALL and MACGREGOR, 2007; LAMORDE et al., 2011; STOHR et al., 2008). Potential bioactivation pathways of NVP involve the substitution of the C-3 or C-12 through the formation of quinone methides or reactive epoxide intermediates leading to DNA or protein adducts, which have an immunogenic potential [figure 1.11 (SHARMA et al., 2012; SHARMA et al., 2013b)].   
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1.5.2 Nevirapine-induced hypersensitivity reactions Even though NVP-containing regimens are generally well tolerated, approximately 5% of NVP-treated patients develop HSRs within the first six weeks of medication. Nevirapine can cause different types of reactions, including combinations of rash, fever and hepatotoxicity. Rechallenge with NVP leads to rapid occurrence of more severe reactions (GANGAR et al., 2000; POLLARD 
et al., 1998). An increased risk of rash-associated hepatotoxicity has been associated with higher pretreatment CD4+ T cell count in women (> 250 cells/µl) and men [> 400 cells/µl (BOEHRINGER-INGELHEIM, 2012; TAIWO, 2006)]. Accordingly, NVP is not recommended for postexposure prophylaxis of non-HIV infected individuals with higher CD4+ T cell counts (PATEL et al., 2004; WIT et al., 2008). Subsequent reports have confirmed this association (LYONS et al., 2006; STERN et al., 2003), while others have not found an association between NVP-induced hypersensitivity and CD4+ T cell counts (KNOBEL et al., 2008; PETERS et al., 2010). Additional risk factors associated with NVP-induced HSRs are listed in table 1.6. No direct correlation between NVP plasma levels and HSRs has been reported (WIT et al., 2008). As with other drug-induced HSRs, NVP hypersensitivity has been associated with various genetic polymorphisms (table 1.8) and HLA-alleles (table 1.7) that will be discussed in more detail below.   
Table 1.6: Risk factors for nevirapine-induced hypersensitivity 
Risk factor Type of reaction 
Abnormal ALT/AST levels at baseline Hepatotoxicity 
Female gender Rash 
HBV and/or HCV co-infection Hepatotoxicity 
Detectable plasma viral load in ART-experienced patients Hypersensitivity 
Concomitant use of alcohol, methadone and isoniazid Hepatotoxicity 
(Adapted from: BERSOFF-MATCHA et al., 2001; TAIWO, 2006; TORTI et al., 2007; WIT et al., 2008)   
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Cutaneous adverse reactions Rash is the most common adverse reaction observed in approximately 35% of NVP patients initiating therapy at 400 mg per day (BARNER and MYERS, 1998; HAVLIR et al., 1996). The majority of these rashes are mild and lack the involvement of mucous membranes and systemic symptoms. More severe reactions can manifest as DRESS and in 0.3% of cases as SJS or TEN (POLLARD et 
al., 1998; TAIWO, 2006). A lower lead-in dose of 200 mg NVP per day for the first two weeks of therapy, followed by 400 mg per day, has been shown to reduce the incidence of rash to 17% (CHEESEMAN et al., 1993; POLLARD et al., 1998). However, patients initiating NVP-therapy at lower concentrations are still at risk of developing NVP-induced cutaneous ADRs (FAGOT et al., 2001; METRY et al., 2001). Severe rash is more common in women than in men (BERSOFF-MATCHA et 
al., 2001; TAIWO, 2006). Only a few animal models have addressed the specificity of idiosyncratic drug reactions in humans. Nevirapine-induced skin rash in rats has very similar characteristics to the mild from of rash observed in patients. Female Brown Norway rats are more susceptible to rash than males and it takes 2-3 weeks for the rash to develop. Rechallenge results in a rapid onset of a more severe reaction. Depletion of CD4+ T cells confers partial protection against rash in rats, which is consistent with the observation that patients with lower CD4+ T cell counts are less likely to develop HSRs (SHENTON et al., 2005; SHENTON et al., 2003). This model further supports the hypothesis that the NVP-induced rash is immune-mediated. Hydroxylation of NVP, leading to the formation of 12-OH-NVP, is the metabolic pathway responsible for the development rash in rats (CHEN et al., 2008a). It causes the formation of a benzylic sulphate, which binds covalently to cytosolic proteins thus initiating an active immune response and may indicate that the underlying mechanism of NVP-induced skin rash in rats is based on the hapten and danger hypotheses [figure 1.11 (SHARMA et al., 2013a; SHARMA et al., 2013b)]. The immune-mediated reaction observed in rats is characterised by the upregulation of either intracellular adhesion molecule (ICAM)-1 or MHC class II receptors and infiltration of macrophages into the 
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dermis. Additionally, lymphocyte infiltration and elevated cytokine levels were detected in NVP-treated animals (CHEN et al., 2009).  Likewise in patients, lesions in the epidermis and dermis are strongly infiltrated by CD4+ and CD8+ T cells (NASSIF et al., 2002; PICHLER, 2003). MPE patients show a strong migration of CD4+ T cells to the epidermis, whereas CD8+ T cells are more numerous in patients with SJS/TEN (HARI et al., 2001; WETTER and CAMILLERI, 2010; YAWALKAR et al., 2000). Macrophages were also found in the dermal infiltrate and may enhance the pro-inflammatory response through phagocytosis and antigen-presentation (PAQUET and PIERARD, 2002). Besides the cytotoxic properties of CD8+ T cells, the release of various cytokines and chemotactic molecules by CD4+ T cells and activated macrophages may mobilise neutrophils, thus contributing to epidermal cell death and inflammatory response (CAPRONI et al., 2006; PICHLER et al., 2002).  
NVP-associated hepatotoxicity Hepatotoxicity has been associated with all classes of antiretrovirals and can be classified as less severe events with abnormal elevations of ALT/AST levels (> 5x upper limit of normal (ULN)) in the presence or absence of symptoms of liver injury. Five to ten per cent of HIV-positive patients on HAART show asymptomatic elevations in ALT/AST levels with no difference in the incidence of NVP-induced elevations compared to other NNRTIs (STERN et al., 2003). Asymptomatic ALT/AST elevations represent transient events that resolve spontaneously. Symptomatic elevations of ALT/AST are associated with systemic symptoms such as nausea, abdominal pain, fever and rash. These reactions occur in 4.9% of NVP-hypersensitive patients of whom 2.2% develop rash-associated symptomatic hepatic events (DIETERICH et al., 2004) and require discontinuation of NVP treatment. Hepatic failure, the most severe case of drug-induced hepatotoxicity, occurs in 0.3% of NVP-treated patients and is characterised as progressive liver injury associated with elevated ALT levels, systemic symptoms as well as jaundice (DIETERICH et al., 2004; TAIWO, 2006). Associated risk factors comprise alcohol use, HBV or HCV co-infections and high 
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baseline ALT/AST levels whereas the associations of elevated CD4+ T cell counts and gender were inconsistent (DIETERICH et al., 2004; STERN et al., 2003).  
1.5.3 Pharmacogenetics of nevirapine-induced 
hypersensitivity Based on the observation that NVP hypersensitivity is essentially dose-independent and lower CD4+ T cell count at treatment initiation can be protective in some patients, the majority of pharmacogenetic studies have focused on the MHC gene loci. In contrast to the ABC hypersensitivity syndrome, a number of both MHC class I and class II alleles have been associated with NVP-induced HSRs in different populations (summarised in table 1.6). First reported in a Western Australian population, HLA-DRB1*01:01 in combination with high CD4+ T cell counts was associated with the occurrence of hepatotoxicity (MARTIN et al., 2005). Subsequently, several other alleles of the DRB1*01 family have been associated with cutaneous and hepatic reactions in populations originating from Europe and Western Australia [DRB1*01 (VITEZICA et al., 2008; YUAN et al., 2011), 
DRB1*01:01 (PHILLIPS et al., 2011) and DRB1*01:02 (PHILLIPS et al., 2013)]. MHC class I alleles belonging to the B*35 family have been primarily implicated in NVP-induced cADRs in Caucasians [B*35:01 (PHILLIPS et al., 2011)], Indians [B*35 (CHANTARANGSU et al., 2009)] and Thai [B*35 and B*35:05 (UMAPATHY et al., 2011; YUAN et al., 2011)], whereas B*58:01 has been associated with hepatotoxicity in a mixed population from Europe (PHILLIPS et al., 2013). More recently, various groups have indicated a strong association between HLA-C*04 and NVP-induced hypersensitivity and cADRs in Asians, Black Africans, Caucasians, Han Chinese and Thai (CARR et al., 2013; GAO et al., 2012; LIKANONSAKUL et al., 2009; YUAN et al., 2011). The association of HLA-C*08 and the C*08-B*14 haplotype with NVP hypersensitivity was described in a Japanese and a Sardinian population, respectively (GATANAGA et al., 2007; LITTERA et al., 2006). Later, the B*35-C*04 and B*15-DR*15 haplotypes were associated with HSRs in NVP-treated patients from Southeast Asia and Western Australia 
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(PHILLIPS et al., 2011; YUAN et al., 2011). Similar to CBZ, NVP hypersensitivity has been associated with different MHC alleles across various populations yet these associations appear to be phenotype specific. Whether the differences in allele frequencies may help to explain the diverse associations has not been investigated.  
Table 1.7: HLA-alleles associated with an increased risk of nevirapine-induced 
hypersensitivity 
HLA-allele Adverse reaction Population OR Reference 
B*15-DR*15 
haplotype 
Fever and hepatitis 
and/or rash Caucasians 8.9 (PHILLIPS et al., 2011) 
B*35 
Cutaneous adverse 
events/concomitant 
hepatic events 
Thai 5.7 (YUAN et al., 2011) 
Skin rash Indian 3.4 (UMAPATHY et al., 2011) 
B*35-C*04 
haplotype 
Cutaneous adverse 
events/concomitant 
hepatic events 
Asians  18.4 
(YUAN et al., 2011) 
Thai 13.4 
B*35:01 Fever and hepatitis and/or rash Caucasians 5.4 (PHILLIPS et al., 2011) 
B*35:05 Skin rash Thai 19.0 (CHANTARANGSU et al., 2009) 
B*58:01 Hepatotoxicity Mixed 3.2 (PHILLIPS et al., 2013) 
C*04 
Cutaneous adverse 
events/concomitant 
hepatic events 
Asians 2.6 
(YUAN et al., 2011) Blacks 5.2 
Whites 1.9 
Skin rash Thai 2.8 (LIKANONSAKUL et al., 2009) 
Hypersensitivity Han Chinese 3.6 (GAO et al., 2012) 
C*04:01 
SJS/TEN Malawians 17.5 
(CARR et al., 2013) 
Hypersensitivity Malawians 2.8 
C*08 Skin rash and/or hepatotoxicity Japanese 6.2 (GATANAGA et al., 2007) 
C*08-B*14 
haplotype 
Skin rash and/or 
hepatotoxicity with 
systemic reactions 
Sardinian NA (LITTERA et al., 2006) 
DRB1*01 
cADRs Caucasians 70.0 (VITEZICA et al., 2008) 
Hepatic adverse events Whites 3.0 (YUAN et al., 2011) 
DRB1*01:01 & 
CD4+ T cells > 
25% 
Fever and hepatitis 
and/or rash Caucasians 8.9 (PHILLIPS et al., 2011) 
Hepatotoxicity with 
multi-system reactions Caucasians 5.5 (MARTIN et al., 2005) 
DRB1*01:02 Hepatotoxicity Mixed 4.6 (PHILLIPS et al., 2013) 
Definitions of adverse reactions as stated by the authors. cADR cutaneous adverse drug reaction, 
HLA human leukocyte antigen, OR odds ratio, SJS Stevens-Johnson syndrome, TEN toxic epidermal 
necrolysis 
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 A small number of groups have investigated the associations of NVP hypersensitivity and genetic polymorphisms in DMEs and drug transporters (table 1.8). Two studies reported an association between the CYP2B6 c.516C>T polymorphism and an increased risk for cADRs in Black Africans and Caucasians (CICCACCI et al., 2013; YUAN et al., 2011). A strong association between the 
CYP2B6 c.983C>T and SJS/TEN was recently described in a Mozambican population (CICCACCI et al., 2013). Hepatotoxicity however, has been associated with a SNP in the ABCB1 transporter (c.3435C>T) in populations originating in the USA, South Africa and Mozambique (CICCACCI et al., 2010; HAAS et al., 2006; RITCHIE et al., 2006). Additionally, a genome wide association study (GWAS) of NVP-induced rash (NIR) in Thai patients has shown the association of two synonymous SNPs that are in complete LD with a nonsynonymous polymorphism of the CCHCR1 gene. CCHCR1 has been implicated in the proliferation of keratinocytes increase susceptibility to psoriasis (ASUMALAHTI et 
al., 2002). The diverse associations reported with NVP hypersensitivity indicate that population-specific differences in genetic, immunological and metabolic pathways may contribute to the pathogenesis of these reactions.  
Table 1.8: Genetic polymorphisms associated with nevirapine-induced 
hypersensitivity  
Gene Adverse reaction Population P -value Reference 
CYP2B6 c.516T>G 
(rs3745274) 
cADRs 
Blacks 0.003 
(YUAN et al., 2011) 
Whites 0.021 
SJS/TEN Mozambicans 0.001 (CICCACCI et al., 2013) 
CYP2B6 c.983C>T 
(rs28399499) SJS/TEN Mozambicans 0.026 (CICCACCI et al., 2013) 
ABCB1 c.3435C>T 
(rs1045642) Hepatotoxicity 
Mixed 0.040 (RITCHIE et al., 2006) 
South Africans 0.016 (HAAS et al., 2006) 
Mozambicans 0.038 (CICCACCI et al., 2010) 
CCHCR1 
(rs126511 and rs746647) Skin rash Thai 1.2 x 10
-8 (CHANTARANGSU et al., 2011) 
Adverse events as defined by the authors. cADR cutaneous adverse drug reaction, CYP cytochrome 
P450 enzyme, HLA human leukocyte antigen, SJS Stevens-Johnson syndrome, TEN toxic epidermal 
necrolysis   
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1.6 Aims of this study Malawi has one of the highest prevalence rates of HIV/AIDS in the world [11% compared to 0.2% and 0.6% in the UK and USA respectively (CENTRAL INTELLIGENCE AGENCY, 2009)]. Currently, over one million people are HIV infected and AIDS is the leading cause of death amongst the 15-49 year olds (UNAIDS, 2012a). Although more beneficial ART regimens are commonly prescribed in developed countries, NVP is widely used as a favourable first-line regimen and the maternal as well as infant MTCT coverage in resource-limited settings like Malawi (DEPARTMENT FOR HIV AND AIDS, 2012). The number of pharmacogenetics studies performed in African populations is rather limited and only very little information is available from Malawi. African populations feature high levels of genetic diversity and data included in public initiatives, such as the 1000 Genome Project and the International HapMap Project, do not address the ethnically and geographically different African groups (GENOMES PROJECT CONSORTIUM et al., 2012; INTERNATIONAL HAPMAP, 2003). This data suggests that pharmacogenetics data acquired in other African populations may not be easily applied to Malawi. The inconsistency among the genetic associations observed in NVP hypersensitivity highlight the need for further research to identify and characterise molecular aspects of NVP-induced HSRs. The aims of this project were therefore: (a) to assess gene expression changes observed in our Malawian population and further characterise these findings in NVP patients as well as healthy volunteers; (b)  to investigate the role of miR-148a and post-transcriptional regulation of HLA-C*04 expression in NVP-hypersensitive patients;  (c) to identify blood-based miRNAs and their potential utility as clinical markers of NVP-induced cutaneous ADRs; (d) and to review and evaluate the relationship between NVP hypersensitivity and HLA-alleles across different populations including the effect of population specific differences in allele frequency.
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2.1 Introduction To identify differentially expressed gene transcripts, gene expression profiling was performed in a black African population of NVP-treated HIV patients from Malawi (manuscript in preparation). Complementary DNA (cDNA) microarray analysis was performed on the Affymetrix GeneChip array and differential gene expression analysis was carried out in blood samples collected from NVP-hypersensitive and tolerant patients. Samples taken from NVP-hypersensitive patients were either classified as acute (taken during the acute phase of the reaction; n = 6) or recovered samples (obtained after drug withdrawal and complete resolution of clinical symptoms; n = 6). In addition six samples from NVP-tolerant were also included in the study. Due to the small number of pre-treatment blood samples available, recovered samples were chosen as the control group. Statistically significant differences in gene expression levels were analysed in contrasts of the acute versus recovered (A vs. R) and tolerant versus recovered (T vs. R) patient groups. Differential gene expression analysis revealed a total of 225 transcripts to be significantly deregulated in NVP-treated patients. The transcripts with the highest fold increases in expression were homologous to CD177, a neutrophil specific antigen, and peptidoglycan recognition protein 1 (PGLYRP1), known to bind murein peptidoglycans of gram-positive bacteria. The expression of the inflammation-associated genes CD177 and PGLYRP1, which are now known as endogenous damage-associated patterns (DAMPs), has been shown to be significantly upregulated in severe skin reactions [SJS and TEN (BELLON et al., 2010)]. Pathway analysis of these results showed granulocyte colony-stimulating factor 3 (CSF3) to be a central partner of the CD177 protein pathway, which controls the production, differentiation and function of granulocytes (figure 2.1).     
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Fig. 2.1: Predicted protein 
interactions illustrating direct 
and indirect associations with 
CD177 
Network generated using the 
Search Tool for the Retrieval of 
INteracting Genes database 
[STRING version 8.2 (SZKLARCZYK et 
al., 2011)]. Differentially expressed 
proteins are shown as small circles 
while other proteins are presented 
as spheres. Blue lines indicate 
binding properties. CSF3 
granulocyte colony-stimulating 
factor, ESAM endothelial cell-
selective adhesion molecule, HBA1 
haemoglobin subunit alpha, 
PECAM-1 platelet endothelial cell 
adhesion molecule, PRTN3 
proteinase 3   Recent findings indicate that the pathogenesis of NVP-induced HSRs is due to a T cell dependent immune response. This is consistent with the associations of different HLA-alleles and NVP hypersensitivity that have been described (summarised in table 1.8). Furthermore higher CD4+ T cell counts have been shown to affect the risk of adverse reactions linked to NVP treatment (BOEHRINGER-INGELHEIM, 2012; CARR et al., 2013; TAIWO, 2006). This theory has been further supported by the histopathological findings of immune cell infiltration in lesions in the animal model developed by Shenton et al. (2003) as well as in patients with drug-induced MPE and SJS (PICHLER, 2003; WETTER and CAMILLERI, 2010). Several studies have also shown that T cell migration precedes neutrophilic transmigration in drug-induced acute generalised exanthematous pustulosis (KELLER et al., 2005; SCHAERLI et al., 2004). CD177, also known as NB1, human neutrophil antigen 2a (HNA-2a) and polycythemia rubra vera 1 (PRV-1), is a membrane protein specifically expressed on neutrophils. It was first described in 1971 in several cases of alloimmune neonatal neutropenia (LALEZARI et al., 1971; TEMERINAC et al., 2000). Heterophilic interactions between CD177 and the platelet endothelial cell adhesion molecule-1 (PECAM-1, also known as CD31) have been shown to 
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promote transendothelial migration of CD177-positive neutrophils (see figure 2.2) after stimulation with N-formyl-methionyl-phenyl-alanine [fMLP (BAYAT et 
al., 2010; SACHS et al., 2007)]. Expression of the cell surface protein is restricted to a subpopulation of neutrophils, with the mean population size of CD177-positive neutrophils ranging from 45-65% (CARUCCIO et al., 2004; GOLDSCHMEDING 
et al., 1992; KISSEL et al., 2001; STRONCEK, 2007). It has been shown that the CD177-negative subpopulation lacks membrane expression due to incomplete mRNA transcription, whereas CD177 deficiency is caused by frame shift mutations leading to the insertion of premature stop codons (KISSEL et al., 2002; WOLFF et al., 2003). CD177-deficient people are healthy, but too few studies have been performed to define if lack of CD177 protein expression has an effect on neutrophil function or the immunological and inflammatory response (JANKOWSKA et al., 2011; WOLFF et al., 2003). Additionally, cell surface expression of proteinase-3 (PR3) has been shown to be dependent on CD177 (BAUER et al., 2007; VON VIETINGHOFF et al., 2007). Given these data and the discovery of a NVP-dependent increase in CD177 expression, we hypothesised that neutrophils may contribute to the development and maintenance of NVP hypersensitivity. To determine whether the NVP-dependent increase in CD177 expression plays a role in the pathophysiology of NVP hypersensitivity, gene and protein expression profiles of patients as well as healthy, NVP-naïve controls were analysed. The specific aims were to (i) validate the results of the CD177 and PGLYRP1 microarray analysis but also to investigate the gene expression levels of CSF3 in two sets of patient samples from Malawi and (ii) further characterise CD177 gene and protein expression after treatment with NVP in vitro.  
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Fig. 2.2: Schematic diagram depicting the neutrophil recruitment cascade 
Shown are the steps of paracellular neutrophil recruitment from the vasculature to the tissue. 
Selectins regulate the rolling, whereas arrest and adhesion depend primarily upon integrin 
interactions. Adhesion and transmigration is largely controlled by ICAM-1 and PECAM-1. NVP may 
stimulate CD177 expression thus facilitating the preferential transmigration of CD177-positive cells 
through heterophilic interactions with PECAM-1 (adapted from: BORREGAARD, 2010; WOODFIN et al., 
2009). ICAM-1 intracellular adhesion molecule 1, NVP nevirapine, PECAM-1 platelet endothelial cell 
adhesion molecule  
2.2 Methods 
2.2.1 Patients and data collection 
Malawi cohort Between 2007 and 2009, 1117 HIV-1 positive antiretroviral-naïve patients were recruited prospectively at the Queen Elizabeth Central Hospital in Blantyre, Malawi for a nested case-control study (conducted by Dr. Mas Chaponda). Written informed consent was obtained from patients suitable to commence ART (WHO clinical stage 3/4 or CD4+ T cell count below 250 cells/µl). All patients recruited were self-reported black Africans, 16 years or older and started on Triomune-40, a fixed-dose combination of stavudine (40 mg), lamivudine (150 mg) and NVP (200 mg). Patients were followed up for 26 weeks, with clinical and laboratory parameters such as CD4+ T cell count and liver function tests monitored at 0, 6, 14 and 18 weeks, if possible. Due to the 
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low incidence (5%) of NVP-induced hypersensitivity, an additional 177 patients, who developed NVP hypersensitivity and attended the same outpatient clinic, were recruited into the study either as patients presenting de novo in clinic (n = 149) or identified from patient records retrospectively (n = 28) during the same time period. Ethics committees at the Liverpool School of Tropical Medicine and the College of Medicine, Malawi, approved the study. Data on ethnicity, gender, age, weight, height as well as CD4+ T cell count, treatment duration and HSR were collected from all patients. The identification and characterisation of HSRs was performed using the Naranjo Probability Scale [summarised in table 2.1 (NARANJO et al., 1981)]. In accordance with international guidelines, patients with any kind of drug-induced HSRs described below had NVP withdrawn.  Using both clinical data and photographs, phenotypes were retrospectively reviewed by a dermatologist blinded to the initial classification of cases. Patients who presented one of the following hypersensitivity reactions were classified as NVP-hypersensitive patients (CARR et al., 2013): (i) NIR: widespread maculopapular rash without systemic manifestations that deteriorates with treatment continuation; (ii) HSS: widespread rash with systemic manifestations like fever, cough or abnormal liver function tests; (iii) Extensive rash with involvement of at least 2 mucous membranes or skin lesions affecting less than 10% (SJS) or more than 30% (TEN) of the body surface area (FAGOT et al., 2001). Blistering between 10% and 30% of body surface area was labelled SJS/TEN overlap syndrome; (iv) DILI: visible jaundice and/or elevated alanine aminotransferase levels. Although patients who were treated for concomitant tuberculosis or hepatotoxicity, were currently pregnant or had previously received ART were excluded from the study, potential confounding through incomplete clinical information and indigenous herbalism cannot be excluded. The control group consisted of patients treated with NVP for at least six months without the occurrence of any type of hypersensitivity.   
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Table 2.1: Summary of the Naranjo adverse drug reaction probability scale 
Question Yes No Do not know 
Are there previous conclusive reports on this reaction? +1 0 0 
Did the adverse event occur after the suspected drug was 
administered? +2 -1 0 
Did the adverse reaction improve when the drug was discontinued or a 
specific antagonist was administered? +1 0 0 
Did the adverse reaction reappear when the drug was re-administered? +2 -1 0 
Are there alternative causes (other than the drug) that could have on 
their own caused the reaction? -1 +2 0 
Did the reaction reappear when a placebo was given? -1 +1 0 
Was the drug detected in the blood (or other fluids) in concentrations 
known to be toxic? +1 0 0 
Was the reaction more severe when the dose was increased or less 
severe when the dose was decreased? +1 0 0 
Did the patient have a similar reaction to the same or similar drugs in 
any previous exposure? +1 0 0 
Was the adverse event confirmed by any objective evidence? +1 0 0 
The Naranjo criteria summarised above classify the probability that an ADR is related to a specific 
drug. ADRs are assigned to a probability category based on the overall score: definite ADR for a 
score  ≥  9,  probable ADR if the score is 5 to 8, possible ADR for 1 to 4 and doubtful ADR if the score 
is 0 (adapted from: NARANJO et al., 1981). ADR adverse drug reaction  A subset of 47 NVP-treated patients were randomly chosen from the above cohort for further analysis (see figure 2.3 or table 2.2). Of these patients, 30 (21 NVP-hypersensitive and 9 tolerant controls) had 36 in vivo samples available for the gene expression analysis: samples from 17 hypersensitive patients were taken during the HSR (acute); after drug withdrawal and complete resolution of clinical symptoms, a recovered sample was obtained from ten NVP-hypersensitive patients, while samples from nine tolerant patients were also included in the study. The in vitro analysis comprised 52 samples taken from 17 hypersensitive and 16 tolerant patients that were subsequently treated with NVP or dimethyl sulfoxide (DMSO; see section 2.2.2). For the statistical analysis of the in vitro data, only patients with both DMSO and NVP-treated samples were included in the study as fold change (2-ΔΔCT) can only be calculated from paired samples (section 2.2.5). Thus CD177, PGLYRP1 and CSF3 expression in nine hypersensitive patients and nine tolerant controls were analysed.  
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Fig. 2.3: Flowchart depicting the various subsets of Malawian patients that were used 
in this study 
If more samples were available than indicated patients, paired or duplicated samples were used.    
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Table 2.2: Characteristics of Malawian patients 
ID Phenotype Gender Age Weight Height CD4 
Samples 
in vivo in vitro 
A R T DMSO NVP 
NR0142 DILI Female 31 42 1.41 321 x* x* 
  
x† 
NR0152 DILI Male 28 43 1.62 58 x* 
    
NR0154 DILI Female 32 42.2 1.64 248 x* 
    
NH1109 HSS Female 32 52.2 1.6 145 x 
    
NR0034 HSS Male 26 56 1.8 NA 
    
x† 
NR0134 HSS Male 39 52.6 1.64 191 
   
x x 
NR0140 HSS Female 43 44 1.51 656 
   
x x 
NR0141 HSS Female 37 57.1 1.55 235 x x* 
 
xa xa 
NH0516 NIR Male 35 61.8 1.8 98 
    
x† 
NH0834 NIR Male 41 66 1.63 122 
 
x * 
 
x x 
NH1035 NIR Male 35 69.9 1.82 220 x 
    
NH1041 NIR Female 43 47.2 1.5 70 x 
  
x† 
 
NH1060 NIR Female 33 54.1 1.4 332 x 
    
NR0092 NIR Female 35 56.4 1.57 57 
 
x* 
   
NR0145 NIR Female 38 46.1 1.47 173 x 
    
NR0146 NIR Female 26 58.1 1.62 286 x x* 
 
x x 
NR0155 NIR Female 38 56.9 1.68 234 x* 
    
NH0821 SJS Female 43 65 1.71 167 
 
x 
 
x x 
NH0993 SJS Female 34 48.6 1.61 168 
 
x 
  
x† 
NR0049 SJS Female 27 51 1.6 NA 
    
x† 
NR0135 SJS Male 37 60.7 1.73 574    x x 
NR0136 SJS Female 28 56.4 1.62 337    x x 
NR0137 SJS Female 19 54 1.59 161 x     
NR0138 SJS Male 58 57 1.59 522 x*     
NR0139 SJS Female 37 49.2 1.49 172 x* x  x†  
NR0143 SJS Female 54 35.8 1.49 105 x x  x x 
NR0144 SJS Female 23 53 1.72 357 x x*  x x 
NR0153 SJS Male 35 63.6 1.66 371 x     
NH0917 Tolerant Male 37 54.5 1.65 133   x   
NH0957 Tolerant Female 40 66 1.61 7    x†  
NH0959 Tolerant Female 27 46.1 1.56 306   x* x x 
NH0966 Tolerant Male 60 71.1 1.7 43   x*   
NH0967 Tolerant Female 44 79.8 1.49 20   x* x x 
NH0968 Tolerant Male 55 54.7 1.59 58   x* x x 
NH0970 Tolerant Male 39 56 1.67 91   x x†  
NH0973 Tolerant Female 22 53.5 1.6 105   x* x x 
NH0974 Tolerant Female 29 56.7 1.65 192   x x x 
NH0975 Tolerant Female 40 52.4 1.66 263     x† 
NH0980 Tolerant Female 56 47.1 1.48 117   x*   
NH0983 Tolerant Male 35 50.9 1.6 130    x†  
NH1021 Tolerant Female 29 48.3 1.63 54     x  † 
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Table 2.2: continued 
ID Phenotype Gender Age Weight Height CD4 
Samples 
in vivo in vitro 
A R T DMSO NVP 
NH1022 Tolerant Male 35 74.2 1.76 165    x x 
NH1023 Tolerant Male 32 48.6 1.64 284    x x 
NH1024 Tolerant Female 41 46.5 1.59 232 
   
x x 
NH1025 Tolerant Male 42 65.4 1.59 242 
    
x† 
NH1026 Tolerant Female 26 57.2 1.58 74 
    
x† 
NH1029 Tolerant Male 53 64.5 1.66 34 
   
x x 
A total of 47 patients were randomly chosen for this study. The in vivo samples taken from patients 
is indicated as A (acute), R (recovered) and T (tolerant). Samples treated with either DMSO or NVP 
are also listed. (*) denotes samples included in the microarray;  (†)  marks  samples  which  were  
excluded from the final analysis as calculation of 2-ΔΔCT was not possible; (a) could not be amplified. 
CD4 CD4+ T cell count, DILI drug-induced liver injury, HSS hypersensitivity syndrome, NIR nevirapine 
induced rash, NVP nevirapine, SJS Stevens-Johnson Syndrome  
Patients and volunteers recruited in Liverpool Six HIV-1 positive, NVP-hypersensitive patients and seven healthy controls were recruited at the University of Liverpool and the Liverpool and Broadgreen University Hospital in 2011 and 2012. Subjects were of self-reported Caucasian or black African ancestry. Ethical approval was granted by the North West Centre Research Ethics Committee (UK) and written informed consent was obtained from all subjects. Healthy controls were recruited prospectively, whereas NVP-hypersensitive patients were recruited retrospectively. Five of the six hypersensitive patients developed NVP-induced HSRs (as classified above) one to nine years before samples were taken and were no longer on NVP containing ART; one patient was recruited during the acute phase of the reaction and samples were taken two days after NVP was withdrawn.  
2.2.2 In vitro culture of whole blood This part of the study was carried out by Dr. Mas Chaponda for samples collected in Malawi and by myself for samples collected in the UK. Whole blood collected in lithium heparin Vacuette® Blood collection tubes (Greiner Bio-One, Germany) was diluted with four volumes of RPMI 1640 media (Sigma Aldrich, USA), containing 100 U/ml penicillin and 100 µg/ml 
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streptomycin. Diluted whole blood was then treated with 25 µM and 50 µM NVP (Sigma Aldrich, USA), which lie within or slightly above the therapeutic range observed in NVP-treated individuals (11–30 µM). In addition, samples collected in Liverpool were treated with 20 µM fMLP (Sigma Aldrich, USA), a chemoattractant that was included as a positive activation control. Studies have shown that 30 min of fMLP treatment is sufficient to induce CD177 protein expression and reproduce inflammatory changes of neutrophils observed in vivo (SACHS et al., 2007; VIDEM and STRAND, 2004). In addition, preliminary flow cytometry analysis showed that the percentage of granulocytes in a heterogeneous leukocyte population decreases from approximately 40% to 10% after 24 hours at standard cell culture conditions (37°C, 5% CO2; data not shown). For this reason, samples collected in Liverpool were incubated for either 30 min or three hours to account for possible time dependent changes in gene and protein expression. However, the only available RNA samples collected in Malawi had been incubated for 24 hours. All samples were incubated under standard cell culture conditions before mRNA and protein expression were analysed as described below. Nevirapine and fMLP were diluted in a 10% DMSO solution to a final concentration of 0.01 M. A 10% DMSO solution was used as vehicle control.  
2.2.3 RNA extraction 
PAXgene Blood RNA extraction of Malawi patient samples Performed by Dr. Mas Chaponda. PAXgene Blood RNA tubes (PreAnalytix, QIAGEN, Germany) were used for the collection of whole blood in Malawi. Total RNA extraction was performed on 
peripheral	  blood	  mononuclear	  cells	  (PBMCs)	  using	  the	  PAXgene™	  Blood	  RNA	  kit	  (PreAnalytix, QIAGEN, Germany), followed by the reduction of alpha- and beta-
globin	  mRNA	  using	   the	  GLOBINclear™	   kit	   (Ambion,	   Applied Biosystems, USA) 
according	  to	  the	  manufacturer’s	  protocol.  
